var title_f27_1_27664="Acute cholecystitis US";
var content_f27_1_27664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute cholecystitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound of the right upper quadrant in a patient with acute cholecystitis reveals marked thickening of the gallbladder wall (arrow) with fluid surrounding the distended gallbladder (arrowhead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_1_27664=[""].join("\n");
var outline_f27_1_27664=null;
var title_f27_1_27665="Linear morphea - limb abnormalities";
var content_f27_1_27665=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55660%7EDERM%2F70426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55660%7EDERM%2F70426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Limb length discrepancy in linear morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 182px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lesions began on the right leg at age five in this patient. Note muscle atrophy, limb length discrepancy and pes planus foot deformity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atrophic morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 171px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe atrophy is present in this patient with linear morphea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_1_27665=[""].join("\n");
var outline_f27_1_27665=null;
var title_f27_1_27666="Patient information: Carcinoid syndrome (The Basics)";
var content_f27_1_27666=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86735\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/17/41237\">",
"          Normal lungs",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/39/37490\">",
"           Upper endoscopy",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"            Transthoracic echocardiogram (echo)",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/5/9299\">",
"         Patient information: Diarrhea in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/41/33426\">",
"         Patient information: Upper endoscopy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/14/7395\">",
"         Patient information: Chronic diarrhea in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Carcinoid syndrome (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H83929724\">",
"      <span class=\"h1\">",
"       What is carcinoid syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Carcinoid syndrome is a group of symptoms that can happen when you have a type of cancer called a carcinoid tumor. Carcinoid tumors can start growing in the digestive tract, lungs, or other parts of the body (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef67527 \" href=\"UTD.htm?40/17/41237\">",
"       figure 2",
"      </a>",
"      ). These tumors sometimes then spread to other parts of the body.",
"     </p>",
"     <p>",
"      Carcinoid syndrome happens with some, but not all, carcinoid tumors. Most commonly, carcinoid syndrome happens when a carcinoid tumor that started in the small intestine spreads to the liver. Carcinoid syndrome happens because carcinoid tumors can make hormones and other substances. These substances can get into the blood. This happens most often after the tumor has spread to the liver. When these substances get into the blood, they can travel around the body and cause symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H83929774\">",
"      <span class=\"h1\">",
"       What are the symptoms of carcinoid syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Episodes of &ldquo;flushing&rdquo; &ndash; Flushing is when your skin gets red or purple and feels hot. This is the most common symptom of carcinoid syndrome. An episode of flushing usually starts suddenly and lasts 30 seconds to 30 minutes. Flushing usually happens on the face, neck, or upper chest. Episodes can sometimes be triggered by certain things, such as eating a big meal or drinking alcohol.",
"       </li>",
"       <li>",
"        Spider veins, called &ldquo;telangiectasias&rdquo; &ndash; These are small, swollen veins that look like purple spots on the skin. They are usually on the nose, cheek, or upper lip.",
"       </li>",
"       <li>",
"        Watery diarrhea that is not bloody",
"       </li>",
"       <li>",
"        Wheezing (noisy breathing) or trouble breathing",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sometimes, carcinoid tumors cause a type of heart disease called &ldquo;carcinoid heart disease.&rdquo; Carcinoid heart disease doesn&rsquo;t always cause symptoms. When it does, it can cause swelling or trouble breathing, or make people feel tired.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H83929789\">",
"      <span class=\"h1\">",
"       Is there a test for carcinoid syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will do an exam. He or she will also order tests to make sure you have carcinoid syndrome and look for carcinoid tumors in your body.",
"     </p>",
"     <p>",
"      Tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Urine tests &ndash; This involves collecting all of the urine you make for 24 hours. This is the test done most often to check whether carcinoid syndrome is the cause of your symptoms.",
"       </li>",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Imaging tests, such as a CT, OctreoScan, or MRI scan &ndash; Imaging tests create pictures of the inside of the body. These tests are usually done to find the location of the carcinoid tumor that is causing your symptoms.",
"       </li>",
"       <li>",
"        Endoscopy &ndash; This is a procedure that lets the doctor look at the inside of your stomach and first part of your small intestine. The doctor will put a thin tube with a camera and light on the end in your mouth and down into your stomach (",
"        <a class=\"graphic graphic_figure graphicRef75392 \" href=\"UTD.htm?36/39/37490\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Echocardiogram (also called an &ldquo;echo&rdquo;) &ndash; This test uses sound waves to create pictures of your heart as it beats (",
"        <a class=\"graphic graphic_figure graphicRef77971 \" href=\"UTD.htm?33/35/34354\">",
"         figure 4",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H83929850\">",
"      <span class=\"h1\">",
"       How is carcinoid syndrome treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on your symptoms, where your carcinoid tumor or tumors are, and how much the cancer has spread in your body. It usually involves 1 or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines that block a carcinoid tumor from making the substances that cause symptoms",
"       </li>",
"       <li>",
"        Anti-diarrhea medicines",
"       </li>",
"       <li>",
"        Surgery to remove all or part of a carcinoid tumor",
"       </li>",
"       <li>",
"        A procedure to block a carcinoid tumor&rsquo;s blood supply, called &ldquo;embolization&rdquo; &ndash; This is done only for tumors in the liver. During this procedure, the doctor blocks off the blood vessel that sends blood to the tumor.",
"       </li>",
"       <li>",
"        Ablation therapy &ndash; This is a procedure that can kill cancer cells. It does not involve surgery. It is done only for tumors in the liver. Doctors can do ablation therapy in different ways. For example, they can use heat or a laser to kill the cancer cells.",
"       </li>",
"       <li>",
"        Chemotherapy &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"       </li>",
"       <li>",
"        Treatment for carcinoid heart disease &ndash; In some cases, this involves surgery to replace a diseased heart valve with a healthy heart valve.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H83929865\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to prevent flushing?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. If you find that certain things trigger your flushing, you can try to avoid those things.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H83929880\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to follow all of your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for carcinoid syndrome involves making many choices, such as what treatment to have. Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H83929895\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=see_link\">",
"       Patient information: Diarrhea in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       Patient information: Upper endoscopy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/14/7395?source=see_link\">",
"       Patient information: Chronic diarrhea in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/1/27666?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86735 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-80A65F7FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_1_27666=[""].join("\n");
var outline_f27_1_27666=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83929724\">",
"      What is carcinoid syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83929774\">",
"      What are the symptoms of carcinoid syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83929789\">",
"      Is there a test for carcinoid syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83929850\">",
"      How is carcinoid syndrome treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83929865\">",
"      Is there anything I can do on my own to prevent flushing?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83929880\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83929895\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86735\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/17/41237\">",
"       Normal lungs",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/39/37490\">",
"        Upper endoscopy",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"         Transthoracic echocardiogram (echo)",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/14/7395?source=related_link\">",
"      Patient information: Chronic diarrhea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=related_link\">",
"      Patient information: Diarrhea in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_1_27667="Subdural hematoma PI";
var content_f27_1_27667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F65181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F65181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Subdural hematoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 567px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A subdural hematoma is bleeding under the tough tissue that covers the brain, called the \"dura.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_1_27667=[""].join("\n");
var outline_f27_1_27667=null;
var title_f27_1_27668="Angiogram clipped basilar aneurysm";
var content_f27_1_27668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F68084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F68084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Clip ligation of cerebral aneurysm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: AP cerebral angiogram demonstrating a basilar summit aneurysm. Right panel: postoperative cerebral angiogram demonstrating clip ligation of the lesion with preserved parent vessel patency.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Guy Rordorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_1_27668=[""].join("\n");
var outline_f27_1_27668=null;
var title_f27_1_27669="White blood cell cast I";
var content_f27_1_27669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54319%7ENEPH%2F68147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54319%7ENEPH%2F68147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Photomicrograph of urine sediment with white blood cell cast (I)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    White cell cast in which blue stained white cells (arrow) are contained within a granular cast.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Frances Andrus, BA, Victoria Hospital, London, Ontario.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Photomicrograph of urine sediment with white blood cell cast (II)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A white blood cell cast, three-quarters of which is filled with leukocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Frances Andrus, BA, Victoria Hospital, London, Ontario.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_1_27669=[""].join("\n");
var outline_f27_1_27669=null;
var title_f27_1_27670="Spherocytes";
var content_f27_1_27670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F70611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F70611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spherocytes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear shows multiple spherocytes which are small, dark, dense hyperchromic red cells without central pallor (arrows). These findings are compatible with hereditary spherocytosis or autoimmune hemolytic anemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal peripheral blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_1_27670=[""].join("\n");
var outline_f27_1_27670=null;
var title_f27_1_27671="Pulsed wave Doppler pulmonary venous flow";
var content_f27_1_27671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F87117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F87117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 676px\">",
"   <div class=\"ttl\">",
"    Pulsed wave Doppler pulmonary venous flow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 656px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    From an apical four-chamber view, a pulse wave sample volume is positioned at the entrance of the right superior pulmonary vein showing the characteristic systolic \"s\" (1) and diastolic \"d\" (2) wave velocities in addition to flow reversal during atrial contraction \"a\" (3) wave.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_1_27671=[""].join("\n");
var outline_f27_1_27671=null;
var title_f27_1_27672="Limit of viability";
var content_f27_1_27672=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Limit of viability",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/1/27672/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/1/27672/contributors\">",
"     Richard E Ehrenkranz, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/1/27672/contributors\">",
"     Mark R Mercurio, MD, MA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/1/27672/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/1/27672/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/1/27672/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/1/27672/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/1/27672/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H8144822\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limit of viability is defined as the stage of fetal maturity that ensures a reasonable chance of extrauterine survival. Determining the limit of viability is desirable so that interventions that are costly and painful can be avoided in the infant who does not have a chance of survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/1\">",
"     1",
"    </a>",
"    ]. However, deciding upon a threshold of viability is challenging because it remains uncertain which extremely preterm infants have a reasonable chance of survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survival and morbidity of extremely premature infants born below 26 weeks gestation will be reviewed here. In addition, a management approach for infants born at the limit of viability based upon prognosis will be presented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8144829\">",
"    <span class=\"h1\">",
"     SURVIVAL RATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that affect survival rates in extremely premature infants (gestational age &lt;26 weeks) include gestational age, birth weight, gender, plurality, and the use of antenatal corticosteroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8144836\">",
"    <span class=\"h2\">",
"     Gestational age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major factor in determining viability is gestational age. Survival rates reported in eight studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/2,3,7-13\">",
"     2,3,7-13",
"    </a>",
"    ] during the initial NICU admission for infants 22 to 25 completed weeks gestation",
"    <span class=\"nowrap\">",
"     (22",
"     <sup>",
"      0/7",
"     </sup>",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     25",
"     <sup>",
"      6/7",
"     </sup>",
"    </span>",
"    weeks gestation) are displayed in the table (",
"    <a class=\"graphic graphic_table graphicRef75260 \" href=\"UTD.htm?5/28/5582\">",
"     table 1",
"    </a>",
"    ). These reports span time periods ranging from six months to six years between 1994 and 2010, and represent several large geographic areas in Western Europe, Japan, and a network of tertiary level academic centers in the United States. These data clearly demonstrated the rise of survival rate as gestational age increased from 22 to 25 weeks. In addition, they also showed improved survival, as survival rates increased significantly for infants born at 23 to 25 weeks gestation. However, it remains uncertain whether the survival rates for infants born at 22 weeks gestation have improved over time.",
"   </p>",
"   <p>",
"    These data emphasize the importance of basing discussions about delivery room management for infants at borderline viability upon the latest available data. In addition, although these results highlight the impact of gestational age on viability, it is important to recognize that ascertaining an accurate gestational age is challenging. Thus, reliance on estimated gestational age may not truly reflect the prognosis. (See",
"    <a class=\"local\" href=\"#H8144879\">",
"     'Interpreting the data'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22068?source=see_link\">",
"     \"Postnatal assessment of gestational age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=see_link\">",
"     \"Prenatal assessment of gestational age\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8144843\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors that impact survival in extremely premature infants include birth weight at a given gestational age, gender, plurality, and the use of antenatal corticosteroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/3,5,6,14\">",
"     3,5,6,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101805021\">",
"    <span class=\"h2\">",
"     Estimates of survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of factors on survival and the probability of a reasonable outcome in infants at or below 25 weeks gestation was illustrated by a report from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network, which evaluated survival and neurodevelopmental outcome for 4446 infants born at 22 to 25 weeks of gestation between 1998 and 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8144857\">",
"     'Neurodevelopmental outcome'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    Multiple regression analysis showed that, in addition to increasing gestational age, the following four factors were associated with improved survival and outcome:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      100 g increments in birth weight at a given gestational age",
"     </li>",
"     <li>",
"      Female sex",
"     </li>",
"     <li>",
"      Use of antenatal glucocorticoids",
"     </li>",
"     <li>",
"      Singleton birth",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A web-based tool based upon this study is available to estimate outcome: (",
"    <a class=\"external\" href=\"file://www.nichd.nih.gov/about/org/der/branches/ppb/programs/epbo/pages/epbo_case.aspx\">",
"     file://www.nichd.nih.gov/about/org/der/branches/ppb/programs/epbo/Pages/epbo_case.aspx",
"    </a>",
"    ). Data used for this tool were not intended to be predictive of individual infant outcomes. As a result, the NICHD tool provides a range of possible outcomes based on patient characteristics and is applicable only at birth. If this tool is used, clinicians need to consider whether other factors are present that impact outcome, such as the negative effects of long-standing fetal compromise",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    maternal and fetal infection, and the potential positive effects of intensive intervention. In conclusion, this tool is a guide that provides the possible range of outcomes based on patient characteristics, and it is not intended to be the sole basis for care decisions, so the clinician must consider other relevant factors when counseling parents regarding management decisions.",
"   </p>",
"   <p>",
"    In a study from the United Kingdom, similar results were reported that factors that impacted on survival were gestational age, birth weight, and gender [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8144850\">",
"    <span class=\"h1\">",
"     MORBIDITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant morbidities that occur in infants 22 to 25 weeks gestation who survived their initial NICU admission include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe intraventricular hemorrhage (ie, grade III and IV) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42697?source=see_link\">",
"       \"Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Periventricular leukomalacia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33913?source=see_link\">",
"       \"Periventricular leukomalacia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Necrotizing enterocolitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41591?source=see_link\">",
"       \"Clinical features and diagnosis of necrotizing enterocolitis in newborns\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bronchopulmonary dysplasia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link\">",
"       \"Pathogenesis and clinical features of bronchopulmonary dysplasia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Severe retinopathy of prematurity (ie, &ge; Stage 3) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=see_link&amp;anchor=H12#H12\">",
"       \"Retinopathy of prematurity\", section on 'Stage'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Late-onset infection &nbsp;",
"     </li>",
"     <li>",
"      Neurodevelopmental impairment (see",
"      <a class=\"local\" href=\"#H8144857\">",
"       'Neurodevelopmental outcome'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34922?source=see_link&amp;anchor=H6#H6\">",
"       \"Long-term neurodevelopmental outcome of premature infants\", section on 'Extremely preterm infant'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rates of these morbidities based on gestational age are displayed in the linked table (",
"    <a class=\"graphic graphic_table graphicRef69552 \" href=\"UTD.htm?0/6/106\">",
"     table 2",
"    </a>",
"    ). Although the rates of these morbidities are often thought to increase with decreasing gestational age, these results demonstrate little overall variation in the incidence of these complications among survivors born between 22 and 25 weeks gestation. Severe retinopathy requiring surgical intervention is the one exception, which increases in incidence with decreasing gestational age. These data are derived from the previously mentioned eight studies that spanned the time period between 1994 and 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/2,3,7-12\">",
"     2,3,7-12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8144836\">",
"     'Gestational age'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8144857\">",
"    <span class=\"h2\">",
"     Neurodevelopmental outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor neurodevelopment outcome is a major long-term complication of extremely premature survivors and includes impaired cognition, and motor and neurosensory deficits. The prevalence of these impairments from three cohorts of survivors following birth at 22 to 25 weeks gestation is displayed in the linked table (",
"    <a class=\"graphic graphic_table graphicRef63848 \" href=\"UTD.htm?38/44/39629\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/3,16\">",
"     3,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As shown in the table (",
"    <a class=\"graphic graphic_table graphicRef63848 \" href=\"UTD.htm?38/44/39629\">",
"     table 3",
"    </a>",
"    ), the neurodevelopmental outcomes of premature infants born between 23 and 25 weeks gestation that were reported by two population-based cohort studies (EPICure study from the British Isles and EPIPAGE study from France) did not differ substantially despite different clinical management approaches, including differences in the immediate post-delivery care [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/16\">",
"     16",
"    </a>",
"    ]. Little overall variation was noted among rates of cerebral palsy (CP) and cognitive scores &lt;70 on the Kaufman Assessment Battery for Children (K-ABC test) by week of gestation when the infants were evaluated at two to three years of age and again at five to six years of age. These findings demonstrate the impact of extreme prematurity on long-term neurodevelopmental outcome and suggest that gestational age had a greater impact upon outcome than do clinical practice differences.",
"   </p>",
"   <p>",
"    A study from the NICHD Neonatal Research Network reported the incidence of the composite outcomes of death, or any neurodevelopmental impairment and death, or profound impairment in the cohort of survivors (",
"    <a class=\"graphic graphic_table graphicRef63848 \" href=\"UTD.htm?38/44/39629\">",
"     table 3",
"    </a>",
"    ), as well as the survival rate at 18 to 22 months corrected age (",
"    <a class=\"graphic graphic_table graphicRef75260 \" href=\"UTD.htm?5/28/5582\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/3\">",
"     3",
"    </a>",
"    ]. The survival and neurodevelopmental outcome data from this cohort of 22 to 25 week survivors were used to develop the above cited web-based tool. This tool provides an estimate of the risk of death, death or any impairment, and death or profound impairment. In this study, neurodevelopmental impairment was defined as a score of 70 or below on either the Mental Developmental Index (MDI) or the Psychomotor Developmental Index (PDI) of the Bayley Scales of Infant Development-II, moderate or severe CP, bilateral blindness, or bilateral hearing loss requiring amplification. Profound impairment was defined as a MDI or PDI &lt;50 or severe gross motor deficit requiring adult assistance to move.",
"   </p>",
"   <p>",
"    A subsequent publication from the NICHD Neonatal Research Network reported that neurodevelopmental outcomes at 18 to 22 months corrected age for infants born at &lt;25 weeks gestation were unchanged between the time periods of 1999 to 2001 and 2002 to 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term neurodevelopmental outcomes of extremely premature infants are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34922?source=see_link&amp;anchor=H6#H6\">",
"     \"Long-term neurodevelopmental outcome of premature infants\", section on 'Extremely preterm infant'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8144872\">",
"    <span class=\"h1\">",
"     MANAGEMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although critical decisions in the setting of extreme prematurity are particularly challenging, and in some ways unique, every facility that cares for high-risk pregnancies should have a consensus approach to the management of extremely premature infants that is consistently used by all providers. These guidelines regarding management decisions need to be grounded in an understanding of the outcome data and must consider the relevant ethical issues. The benefit of consensus guidelines was demonstrated by the results of a prospective study in which disagreement in the management approach of infants",
"    <span class=\"nowrap\">",
"     23",
"     <sup>",
"      0/7",
"     </sup>",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     26",
"     <sup>",
"      6/7",
"     </sup>",
"    </span>",
"    weeks&rsquo; gestation between obstetricians and neonatologists significantly increased the likelihood of death on the first day of life [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unavoidable ethical questions that the physician must answer include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Should resuscitation and intensive care measures, including such things as intubation, chest compressions, epinephrine, and mechanical ventilation be initiated in the delivery room?",
"     </li>",
"     <li>",
"      Are such measures ethically impermissible, optional, or obligatory?",
"     </li>",
"     <li>",
"      How much of a say should parents have in these decisions?",
"     </li>",
"     <li>",
"      On what should such decisions be based?",
"     </li>",
"     <li>",
"      Once intensive care measures such as mechanical ventilation have been started, is it ever ethically permissible to stop?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A rational approach to these ethical questions will be greatly aided by an understanding of the outcomes data, outlined above, and by addressing the following questions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What are the strengths and weaknesses of the data?",
"     </li>",
"     <li>",
"      What are the relevant ethical issues and principles?",
"     </li>",
"     <li>",
"      What are the recommendations of professional organizations? Are they based on the current evidence and are they applicable in the current clinical setting?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8144879\">",
"    <span class=\"h2\">",
"     Interpreting the data",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173052081\">",
"    <span class=\"h3\">",
"     Survival to discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although extensive mortality and morbidity data for extremely low gestational age infants have been published, one must apply these data with caution because of the challenges in establishing accurate gestational age, and addressing the impact of variability in clinical practice and attitudes on survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173052104\">",
"    <span class=\"h4\">",
"     Accuracy of gestational age",
"    </span>",
"    &nbsp;&mdash;&nbsp;An estimated gestational age can have a margin of error from a few days to two weeks either with prenatal or postnatal assessment.",
"   </p>",
"   <p>",
"    The estimated gestational age of the fetus can be off by a few days if based on very early ultrasound, or by as much as two weeks if based on the date of the last menstrual period",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    second trimester ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/19\">",
"     19",
"    </a>",
"    ]. As a result, a newborn believed to be at 23 weeks could be under 22 weeks (with virtually no chance of survival) or more than 24 weeks, with a better than even chance of survival. For the majority of infants included in the above studies, gestational age was based on best obstetrical estimate, and the estimated gestational age could have a margin of error up to a few days to two weeks. Similarly, in the clinical setting, the estimated gestational age can also be off by days and weeks, unless the fetus is a product of in vitro fertilization (in whom gestational age dating is accurate). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=see_link\">",
"     \"Prenatal assessment of gestational age\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because fetuses mature at different rates with regard to external appearance, most postnatal assessment tools used are only accurate within one to two weeks gestation. Thus, it is not possible to accurately differentiate a child at 23 weeks from one at 22 or 24 weeks based on physical examination in the delivery room. The obstetrical estimate should be used when counseling parents or making decisions unless there is a profound discrepancy between physical appearance and the obstetrical estimate of gestational age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22068?source=see_link&amp;anchor=H5#H5\">",
"     \"Postnatal assessment of gestational age\", section on 'Methods of assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of the method used to estimate gestational age, clinicians should recognize that, for most cases, there will be a margin of error in assigning gestational age. Thus, the gestational age should be considered as a range rather than a discrete number when used to predict the likelihood of survival for an extremely premature infant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191949546\">",
"    <span class=\"h4\">",
"     Impact of initial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another major issue with regard to predicted survival at borderline viability is the impact of initial management [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/20\">",
"     20",
"    </a>",
"    ]. The decision to",
"    <strong>",
"     not",
"    </strong>",
"    provide resuscitation or intensive care measures below a certain gestational age could result in a self-prophetic survival rate of or near zero, which may be reported in the literature and to parents.",
"   </p>",
"   <p>",
"    Therefore, the relevant question regarding survival when considering resuscitation decisions is not whether the child would survive without help, but what the chance of survival would be if every effort were to be made, such as mechanical ventilation. This point is illustrated by the NICHD data and outcome estimator regarding survival at 23 weeks, which predicts a 26 percent survival for all infants born at 23 weeks gestation, but an improved rate of 37 percent for those who were placed on mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/3\">",
"     3",
"    </a>",
"    ]. While this might reflect the fact that some infants died before they could be placed on the ventilator, decisions to withhold mechanical ventilation in some cases, no doubt, contributed to the differences in survival. Support for this last assumption was found in a subsequent NICHD report that found active resuscitation and ventilation were provided in the delivery room for only 68 percent of infants born at 23 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/12\">",
"     12",
"    </a>",
"    ]. In a study from a single center of 100 consecutive infants born at 23 weeks gestation between 1996 and 2006, universal resuscitation resulted in a 40 percent survival rate to discharge similar to the rate seen in the NICHD subgroup that was provided mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact on providing or withholding care is even more apparent when one considers survival at 22 weeks gestation. Although the NICHD data related to extremely premature infants born between 2003 and 2007 showed survival to be 6 percent for infants born at 22 weeks gestation, resuscitation and ventilation were attempted in only 19 percent of this cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/12\">",
"     12",
"    </a>",
"    ]. It is not the intent of this discussion to comment on whether or not it was inappropriate to withhold resuscitation from these infants, but to note that the statistic of 6 percent is misleading to physicians and parents who are deciding on whether to provide resuscitation to an infant at this gestational age. It is also noteworthy that in Japan, where at least some centers appear to be more aggressive at 22 weeks than in the United States or other countries, survival at 22 weeks in one large multicenter series was 34 percent at the time of discharge from the NICU (",
"    <a class=\"graphic graphic_table graphicRef75260 \" href=\"UTD.htm?5/28/5582\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, if care is to be provided to infants at 22 to 23 weeks' gestation, antenatal corticosteroids should be administered to their mothers in preterm labor. A cohort study of prospectively collected data on inborn infants with a birth weight between 401 g and 1000 g born at 22 to 25 weeks' gestation demonstrated that for infants at 23 to 25 weeks' gestation, antenatal exposure to corticosteroids compared with nonexposure was associated with a significantly lower rate of death, death or selected neonatal morbidities, and death or neurodevelopmental impairment at 18 to 22 months corrected age (",
"    <a class=\"graphic graphic_table graphicRef75260 \" href=\"UTD.htm?5/28/5582\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef69552 \" href=\"UTD.htm?0/6/106\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63848 \" href=\"UTD.htm?38/44/39629\">",
"     table 3",
"    </a>",
"    ). For infants at 22 weeks' gestation, antenatal exposure to corticosteroids compared with nonexposure was only associated with a significantly lower rate of death or necrotizing enterocolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/22\">",
"     22",
"    </a>",
"    ]. Furthermore, one report has suggested that increased center rates of aggressive clinical management of pregnancies and infants at 22 to 24 weeks&rsquo; gestation, especially administration of antenatal corticosteroids, was associated with a lower mortality among 22- to 24-week infants and improved outcomes among 25- to 27-week infants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, based on the above discussion, interpretation of survival data should always take into account whether resuscitation was offered because the survival rate varies depending on the degree of assistance given to the infant, particularly those born at or below 23 weeks gestation. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8144886\">",
"    <span class=\"h3\">",
"     Long term morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concern regarding permanent neurodevelopmental impairment for children born at borderline viability plays a role in decisions regarding initial resuscitation and ongoing intensive care. Neurodevelopmental sequelae of extreme prematurity include cognitive impairment, cerebral palsy, visual impairment, hearing impairment, and learning and behavioral difficulties (",
"    <a class=\"graphic graphic_table graphicRef63848 \" href=\"UTD.htm?38/44/39629\">",
"     table 3",
"    </a>",
"    ). However, it is challenging to accurately predict long-term neurodevelopmental outcome for extremely premature survivors.",
"   </p>",
"   <p>",
"    The data most commonly referenced for neurodevelopmental outcome and used in the NICHD outcome estimator [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/3\">",
"     3",
"    </a>",
"    ], are based on follow-up evaluations of survivors at 18 to 22 months corrected age (CA). However, a study of premature survivors (gestational age 22 to 27 weeks) from the Australian Victorian Infant Collaborative Study Group reported a poor correlation between neurodevelopmental evaluation at two and eight years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/24\">",
"     24",
"    </a>",
"    ]. Notably, evaluation at two years of age significantly overestimated the likelihood of moderate or severe disability at an older age, mostly due to differences in classification of cognitive disability between two and eight years of age.",
"   </p>",
"   <p>",
"    Similar concerns about the predictive accuracy of testing at two years of age were noted in a study from a single center in the United States that observed a poor correlation between the test results of the Bayley Scales of Infant Development II performed at 20 months CA and the Kaufman Assessment Battery for Children Mental Processing Composite at eight years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/24\">",
"     24",
"    </a>",
"    ]. The rate of cognitive impairment was lower at school age than at 20 months CA (16 versus 39 percent). In the EPICure data from Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/25\">",
"     25",
"    </a>",
"    ], 86 percent of survivors with severe disability at 30 months had persistent moderate to severe disability at six years of age.",
"   </p>",
"   <p>",
"    These results suggest there is a risk of overestimating moderate or severe disability, particularly cognitive impairment, at a later age when assessing neurodevelopmental status at two to three years of age. As noted above, the NICHD outcome estimator is based on outcome data at 18 to 20 months CA, and this should be taken into account when utilizing this tool to predict long-term outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8144893\">",
"    <span class=\"h2\">",
"     Ethical issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the many ethical issues at play in making management decisions at borderline viability, both in the delivery room and in the NICU, there is considerable debate among ethicists and clinicians on what role these issues should have in the clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One way to approach ethical analysis (though certainly not the only way) is to consider relevant rights of the infant, the rights of the parents, and the obligations of the clinical team.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The infant has a right to life, meaning a right to treatment (when feasible) that has a reasonable chance of saving his or her life. The infant also has a right to mercy, meaning a right not to be subjected to painful procedures that are extremely unlikely to benefit him or her (ie, improve survival",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      decrease morbidity).",
"     </li>",
"     <li>",
"      The parents have a right to information they need to make informed decisions on their child&rsquo;s behalf. They have a right to decide what is done to their child, but that may, in rare situations, be overridden by the child&rsquo;s rights (eg, if they refuse a treatment that clearly would benefit the infant, or demand one that clearly would be harmful to their child).",
"     </li>",
"     <li>",
"      Clinicians have an obligation to present parents with the relevant information, such as morbidity and mortality data (as well as the limitations of those data), and to help them with the profoundly difficult decisions for the care of this age group. An honest presentation of the relevant information and the available options (including, if feasible, transfer to another institution) is paramount. The clinical team should recognize the enormous stress that decision making in this setting causes parents, and work closely with them to reach management decisions together, based primarily on an assessment of the perceived benefits and burdens to the infant of treatments under consideration. In rare circumstances, the clinical team may determine that parental preferences are clearly opposed to the child&rsquo;s interests, in which case those decisions may need to be overridden, by use of proper procedural channels as time allows.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two other important ethical issues to consider are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Withdrawal of treatment &ndash; A central question with regard to intensive care measures for patients of all ages is the ethical permissibility of withdrawing life-sustaining treatments once they have been initiated. In particular, in the earlier years of mechanical ventilation, some felt that it would be impermissible to withdraw mechanical ventilation once begun. At this point there is a consensus among intensivists, neonatologists, and medical ethicists that this is not the case. If, for a given clinical situation and prognosis, it would be permissible not to intubate, then it would also be permissible to extubate and withdraw mechanical ventilation. Thus, an initial decision to resuscitate and initiate intensive care measures is reversible, and parents should be made aware of this [",
"      <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Justice &ndash; A central ethical principle when making resuscitation decisions, or resuscitation policies, is justice. Justice requires us to treat people equally unless there is a relevant difference between them. It would be inappropriate to give one set of parents in a given institution a choice regarding resuscitation of their infant, but tell another set that they have no choice (either resuscitation is obligatory, or not an option), if the two infants are believed to have the same prognosis. To treat them differently requires a relevant difference, and that difference should be prognosis.",
"      <br/>",
"      <br/>",
"      Traditionally, prognosis has been estimated prior to birth primarily by using gestational age. However, the data from the NICHD Neonatal Research Network clearly show that we can be more precise in predictions by also incorporating such factors as gender, weight, antenatal steroids, and singleton versus multiple gestations [",
"      <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/3\">",
"       3",
"      </a>",
"      ]. Thus, a larger female infant will sometimes have a better prognosis than a smaller male who is a week more mature. Basing our parental counseling and options on gestational age alone predisposes our management to injustice and is obsolete. (See",
"      <a class=\"local\" href=\"#H8144843\">",
"       'Other factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on the above ethical approach and considerations, infants at borderline viability can be assigned to one of three management categories for resuscitative and intensive care based on prognosis (ie, mortality and morbidity).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prognosis is so poor that the infant should not be made to undergo any resuscitative and intensive care measures. In this case, these procedures would be impermissible.",
"     </li>",
"     <li>",
"      Prognosis is so good that resuscitative and intensive care measures should be provided, at least initially, and are obligatory.",
"     </li>",
"     <li>",
"      The prognosis is unclear and it is difficult to determine the relative benefit and burden of resuscitative and intensive care measures for the infant. In this setting, physicians generally defer to the values and preferences of informed parents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Defining the boundaries of these three categories, of course, is difficult. Various professional organizations, as shown below, have provided guidelines for that determination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8144900\">",
"    <span class=\"h2\">",
"     Professional standards and recommendations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26390972\">",
"    <span class=\"h3\">",
"     AHA and AAP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Neonatal Resuscitation Textbook [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/29\">",
"     29",
"    </a>",
"    ], published in 2011 by the American Academy of Pediatrics (AAP) and the American Heart Association (AHA), states that below 23 weeks gestation resuscitation may not be indicated due to almost certain early death and unacceptably high morbidity among survivors. At 23 and 24 weeks, where prognosis may be more uncertain, parents&rsquo; views on either initiating or withholding resuscitation should be supported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/29\">",
"     29",
"    </a>",
"    ]. As discussed above, however, the decision not to resuscitate will result in a self-prophetic survival rate of or near zero, which may lead to publication bias. So framing prognosis at 22 weeks as &ldquo;almost certain early death&rdquo; may not be consistent with the most currently available information that show improved survival with more aggressive management as illustrated by the most current NICHD data [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/12\">",
"     12",
"    </a>",
"    ] and data from Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H191949546\">",
"     'Impact of initial management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    2010 guidelines from the AHA, published as a Special Report by the AAP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/30\">",
"     30",
"    </a>",
"    ], state that when gestational age or birth weight are associated with &ldquo;&hellip;almost certain early death and when unacceptably high morbidity is likely among the rare survivors, resuscitation is not indicated. Examples include&hellip;gestational age &lt;23 weeks or birth weight &lt;400 grams.&rdquo; They further note that when &ldquo;survival is borderline, morbidity rate is relatively high, and the anticipated burden to the child is high, parental desires concerning initiation of resuscitation should be supported&rdquo;. This optional status for resuscitation refers to infants born at 23 or 24 completed weeks; the document also states that at gestation &gt; 25 weeks, prognosis is generally such that resuscitation is nearly always &ldquo;indicated&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/30\">",
"     30",
"    </a>",
"    ]. Both the AAP and the AHA underscore the importance of uncertainties in gestational age and prediction, and the need to avoid firm commitment to a plan until the baby has been examined after birth. We suggest, however, that deviating from a plan agreed upon with the parents is only appropriate if information becomes available in the delivery room that significantly alters the previously discussed prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2009, the AAP Committee on Fetus and Newborn (COFN) published their guidelines for antenatal counseling regarding resuscitation at extremely low gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/1\">",
"     1",
"    </a>",
"    ]. These guidelines suggest that predictions provided to parents facing resuscitation decisions should not be based on gestational age alone, but should include &ldquo;all relevant information affecting prognosis.&rdquo; The COFN chose",
"    <strong>",
"     not",
"    </strong>",
"    to give specific gestational age cutoffs to delineate when parents should be given a choice. The following were included in these guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"If physicians involved believe there is",
"      <strong>",
"       no",
"      </strong>",
"      chance of survival, resuscitation is not indicated, and should not be initiated.&rdquo;",
"     </li>",
"     <li>",
"      \"If the physicians consider a good outcome to be very unlikely, the parental choice regarding resuscitation should be respected.\"",
"     </li>",
"     <li>",
"      \"When the physicians' judgement is that a good outcome is reasonably likely, resuscitation should be initiated, and parents and physicians should then work together to make decisions about ongoing intensive care.&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By these guidelines, resuscitation would be withheld despite a parental request for resuscitation only if there were no chance of survival. Based on currently available data, this would seem to suggest that in some cases parents should be given a choice regarding resuscitation at 22 weeks, where the chance of survival is very low but would not be zero. Also, this approach would avoid the apparent injustice of denying the option of neonatal resuscitation and intensive care to parents of a 22 week infant without any other poor prognostic factors, but giving that option to parents of a 23 week infant with a worse prognosis because of the presence of additional poor prognostic factors. (See",
"    <a class=\"local\" href=\"#H8144843\">",
"     'Other factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26391021\">",
"    <span class=\"h3\">",
"     United Kingdom guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United Kingdom, 2006 guidelines from the Nuffield Council on Bioethics included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resuscitation and intensive care should not be standard care for infants born &le;22 weeks but should be carried out if informed parents request it and clinicians agree that it is likely in the child&rsquo;s best interests.",
"     </li>",
"     <li>",
"      For infants at 23 weeks gestation, parents should be given a choice, but physicians need not provide or continue intensive care if they feel that it offers no benefit to the child.",
"     </li>",
"     <li>",
"      For infants at 24 weeks gestation, resuscitation and intensive care should generally be provided but may be withheld if, based on the child&rsquo;s condition, parents and physician agree that it would not be in the child&rsquo;s best interest.",
"     </li>",
"     <li>",
"      For infants &ge;25 weeks, intensive care should generally be initiated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26391071\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the recommendation that every facility that cares for high-risk pregnancies should have a consensus approach to the management of extremely premature infants, we have established an approach to the treatment of infants who are at the threshold of viability based on the currently available evidence, and the values and preferences of fully informed parents. This approach is consistent with published guidelines from the 2009 AAP Committee on Fetus and Newborn [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27672/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our general approach to resuscitation and intensive care measures at borderline viability is as follows. Exceptions may be made at the discretion of the attending physician if there is additional evidence that significantly worsens the prognosis (eg, certain congenital anomalies or profound growth retardation).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Below 22 weeks gestation &ndash; Resuscitation is not offered or provided due to the zero or near zero chance of survival.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       22",
"       <sup>",
"        0/7",
"       </sup>",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       22",
"       <sup>",
"        6/7",
"       </sup>",
"      </span>",
"      weeks of gestation &ndash; Resuscitation is offered to parents if there is at least a small chance of survival based on available information (eg, the NICHD outcome estimator for patients receiving mechanical ventilation) and is then provided only if requested by informed parents.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       23",
"       <sup>",
"        0/7",
"       </sup>",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       23",
"       <sup>",
"        6/7",
"       </sup>",
"      </span>",
"      weeks of gestation &ndash; Resuscitation is offered to parents but provided or withheld based on the preference of informed parents.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       24",
"       <sup>",
"        0/7",
"       </sup>",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       24",
"       <sup>",
"        6/7",
"       </sup>",
"      </span>",
"      weeks of gestation &ndash; Resuscitation is offered to parents and may be provided or withheld based on the preference of informed parents. However, if the newborn is predicted to have greater than 50 percent chance of survival without neurodevelopmental impairment, resuscitation is provided. That likelihood is determined using the NICHD database outcome predictor for patients given mechanical ventilation, and using best obstetrical estimate of gestational age and estimated fetal weight.",
"     </li>",
"     <li>",
"      25 weeks of gestation and higher &ndash; Resuscitation is provided.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8144907\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limit of viability is defined as the stage of fetal maturity that ensures a reasonable chance of survival. Determining the limit of viability is desirable so that costly and painful interventions can be avoided in the infant who does not have a chance of survival. However, deciding upon a threshold of viability is challenging because it remains uncertain which extremely preterm infant has a reasonable chance of survival.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Factors that affect survival rates for extremely premature infants (gestational age below 26 weeks) include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Gestational age is the major factor in determining viability (",
"      <a class=\"graphic graphic_table graphicRef75260 \" href=\"UTD.htm?5/28/5582\">",
"       table 1",
"      </a>",
"      ); however, there is a significant margin of error (eg, few days to two weeks) in the estimation of gestational age using either prenatal or postnatal assessment tools. (See",
"      <a class=\"local\" href=\"#H8144836\">",
"       'Gestational age'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H173052104\">",
"       'Accuracy of gestational age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other factors that affect survival rate include birth weight at a given gestational age, gender, plurality, and the use of antenatal corticosteroid therapy. (See",
"      <a class=\"local\" href=\"#H8144843\">",
"       'Other factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A web-based tool from the National Institute of Child Health and Human Development (NICHD) is available to estimate outcome based on gestational age, birth weight at a given gestational age, gender, plurality, and the use of antenatal corticosteroid therapy (",
"      <a class=\"external\" href=\"file://www.nichd.nih.gov/about/org/der/branches/ppb/programs/epbo/pages/epbo_case.aspx\">",
"       file://www.nichd.nih.gov/about/org/der/branches/ppb/programs/epbo/Pages/epbo_case.aspx",
"      </a>",
"      ). This tool provides a range of possible outcome and should not be the sole basis for parental counseling and clinical decision making.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant morbidities of extremely premature survivors include severe intraventricular hemorrhage (ie, grade III and IV), periventricular leukomalacia, necrotizing enterocolitis, bronchopulmonary dysplasia, severe retinopathy of prematurity (ie, &ge; Stage 3), late-onset infection, and neurodevelopmental impairment (",
"      <a class=\"graphic graphic_table graphicRef69552 \" href=\"UTD.htm?0/6/106\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef63848 \" href=\"UTD.htm?38/44/39629\">",
"       table 3",
"      </a>",
"      ). Other than retinopathy of prematurity that requires surgical intervention, there is little overall variation in the morbidity rates based on gestational age among extremely premature survivors. (See",
"      <a class=\"local\" href=\"#H8144850\">",
"       'Morbidity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Every facility that cares for high-risk pregnancies should have a consensus approach to the management of extremely premature infants that is consistently used by all providers. In our practice, the approach we use in managing these infants is based on the currently best available data on survival and morbidity, and review of the relevant ethical issues and principles. We also consider the recommendations of the pertinent professional organizations. (See",
"      <a class=\"local\" href=\"#H8144872\">",
"       'Management approach'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Based on the currently available evidence and consideration of the relevant ethical issues, we suggest using the following guidelines in the care of the extremely premature infant (gestational age &lt;26 weeks) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26391071\">",
"       'Our approach'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Exceptions may be made at the discretion of the attending physician if there is additional evidence that significantly worsens the prognosis (eg, certain congenital anomalies or profound growth retardation).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Below 22 weeks gestation &ndash; Resuscitation is not offered or provided due to the zero or near zero chance of survival.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       22",
"       <sup>",
"        0/7",
"       </sup>",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       22",
"       <sup>",
"        6/7",
"       </sup>",
"      </span>",
"      weeks of gestation &ndash; Resuscitation is offered to parents if there is at least a small chance of survival based on available information (eg, the NICHD outcome estimator for patients receiving mechanical ventilation) and is then provided only if requested by informed parents.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       23",
"       <sup>",
"        0/7",
"       </sup>",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       23",
"       <sup>",
"        6/7",
"       </sup>",
"      </span>",
"      weeks of gestation &ndash; Resuscitation is offered to parents but provided or withheld based on the preference of informed parents.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       24",
"       <sup>",
"        0/7",
"       </sup>",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       24",
"       <sup>",
"        6/7",
"       </sup>",
"      </span>",
"      weeks of gestation &ndash; Resuscitation is offered to parents and may be provided or withheld based on the preference of informed parents. However, if the newborn is predicted to have greater than 50 percent chance of survival without neurodevelopmental impairment, resuscitation is provided. That likelihood is determined using the NICHD database outcome predictor for patients given mechanical ventilation, and using best obstetrical estimate of gestational age and estimated fetal weight.",
"     </li>",
"     <li>",
"      25 weeks of gestation and higher &ndash; Resuscitation is provided.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/1\">",
"      Batton DG, Committee on Fetus and Newborn. Clinical report--Antenatal counseling regarding resuscitation at an extremely low gestational age. Pediatrics 2009; 124:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/2\">",
"      Field DJ, Dorling JS, Manktelow BN, Draper ES. Survival of extremely premature babies in a geographically defined population: prospective cohort study of 1994-9 compared with 2000-5. BMJ 2008; 336:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/3\">",
"      Tyson JE, Parikh NA, Langer J, et al. Intensive care for extreme prematurity--moving beyond gestational age. N Engl J Med 2008; 358:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/4\">",
"      Seri I, Evans J. Limits of viability: definition of the gray zone. J Perinatol 2008; 28 Suppl 1:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/5\">",
"      Modi N. Survival after extremely preterm birth. BMJ 2008; 336:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/6\">",
"      Bader D, Kugelman A, Boyko V, et al. Risk factors and estimation tool for death among extremely premature infants: a national study. Pediatrics 2010; 125:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/7\">",
"      Costeloe K, Hennessy E, Gibson AT, et al. The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability. Pediatrics 2000; 106:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/8\">",
"      Larroque B, Br&eacute;art G, Kaminski M, et al. Survival of very preterm infants: Epipage, a population based cohort study. Arch Dis Child Fetal Neonatal Ed 2004; 89:F139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/9\">",
"      Markestad T, Kaaresen PI, R&oslash;nnestad A, et al. Early death, morbidity, and need of treatment among extremely premature infants. Pediatrics 2005; 115:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/10\">",
"      Itabashi K, Horiuchi T, Kusuda S, et al. Mortality rates for extremely low birth weight infants born in Japan in 2005. Pediatrics 2009; 123:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/11\">",
"      EXPRESS Group, Fellman V, Hellstr&ouml;m-Westas L, et al. One-year survival of extremely preterm infants after active perinatal care in Sweden. JAMA 2009; 301:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/12\">",
"      Stoll BJ, Hansen NI, Bell EF, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010; 126:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/13\">",
"      Seaton SE, King S, Manktelow BN, et al. Babies born at the threshold of viability: changes in survival and workload over 20 years. Arch Dis Child Fetal Neonatal Ed 2013; 98:F15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/14\">",
"      Kugelman A, Bader D, Lerner-Geva L, et al. Poor outcomes at discharge among extremely premature infants: a national population-based study. Arch Pediatr Adolesc Med 2012; 166:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/15\">",
"      Manktelow BN, Seaton SE, Field DJ, Draper ES. Population-based estimates of in-unit survival for very preterm infants. Pediatrics 2013; 131:e425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/16\">",
"      Bodeau-Livinec F, Marlow N, Ancel PY, et al. Impact of intensive care practices on short-term and long-term outcomes for extremely preterm infants: comparison between the British Isles and France. Pediatrics 2008; 122:e1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/17\">",
"      Hintz SR, Kendrick DE, Wilson-Costello DE, et al. Early-childhood neurodevelopmental outcomes are not improving for infants born at &lt;25 weeks' gestational age. Pediatrics 2011; 127:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/18\">",
"      Guinsburg R, Branco de Almeida MF, Dos Santos Rodrigues Sadeck L, et al. Proactive management of extreme prematurity: disagreement between obstetricians and neonatologists. J Perinatol 2012; 32:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/19\">",
"      Donovan EF, Tyson JE, Ehrenkranz RA, et al. Inaccuracy of Ballard scores before 28 weeks' gestation. National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1999; 135:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/20\">",
"      Mercurio MR. The ethics of newborn resuscitation. Semin Perinatol 2009; 33:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/21\">",
"      Batton DG, DeWitte DB, Pryce CJ. One hundred consecutive infants born at 23 weeks and resuscitated. Am J Perinatol 2011; 28:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/22\">",
"      Carlo WA, McDonald SA, Fanaroff AA, et al. Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks' gestation. JAMA 2011; 306:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/23\">",
"      Smith PB, Ambalavanan N, Li L, et al. Approach to infants born at 22 to 24 weeks' gestation: relationship to outcomes of more-mature infants. Pediatrics 2012; 129:e1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/24\">",
"      Roberts G, Anderson PJ, Doyle LW, Victorian Infant Collaborative Study Group. The stability of the diagnosis of developmental disability between ages 2 and 8 in a geographic cohort of very preterm children born in 1997. Arch Dis Child 2010; 95:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/25\">",
"      Marlow N, Wolke D, Bracewell MA, et al. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 2005; 352:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/26\">",
"      Mercurio MR. Physicians' refusal to resuscitate at borderline gestational age. J Perinatol 2005; 25:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/27\">",
"      Mercurio MR. Parental authority, patient's best interest and refusal of resuscitation at borderline gestational age. J Perinatol 2006; 26:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/28\">",
"      Wellesley H, Jenkins IA. Withholding and withdrawing life-sustaining treatment in children. Paediatr Anaesth 2009; 19:972.",
"     </a>",
"    </li>",
"    <li>",
"     American Heart Association and American Academy of Pediatrics. Neonatal Resuscitation, 6th ed, Kattwinkel J (Ed), American Academy of Pediatrics, Elk Grove Village 2011. p.5.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/30\">",
"      Kattwinkel J, Perlman JM, Aziz K, et al. Neonatal resuscitation: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Pediatrics 2010; 126:e1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27672/abstract/31\">",
"      D'Angio CT, Mercurio MR. Evidence-based ethics in the 'gray zone' of neonatal viability: promises and limitations. Pediatr Health 2008; 2:777.",
"     </a>",
"    </li>",
"    <li>",
"     Nuffield Council on Bioethics. Guidelines on giving intensive care to premature babies. 2006. file://www.nuffieldbioethics.org/neonatal-medicine/neonatal-medicine-background-extremely-premature-babies (Accessed on February 07, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13511 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.81.197.98-881851AA78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_1_27672=[""].join("\n");
var outline_f27_1_27672=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8144907\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8144822\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8144829\">",
"      SURVIVAL RATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8144836\">",
"      Gestational age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8144843\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H101805021\">",
"      Estimates of survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8144850\">",
"      MORBIDITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8144857\">",
"      Neurodevelopmental outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8144872\">",
"      MANAGEMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8144879\">",
"      Interpreting the data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H173052081\">",
"      - Survival to discharge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H173052104\">",
"      Accuracy of gestational age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H191949546\">",
"      Impact of initial management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8144886\">",
"      - Long term morbidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8144893\">",
"      Ethical issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8144900\">",
"      Professional standards and recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26390972\">",
"      - AHA and AAP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26391021\">",
"      - United Kingdom guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26391071\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8144907\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/13511\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/13511|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/28/5582\" title=\"table 1\">",
"      Survival rates for extremely premature infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/6/106\" title=\"table 2\">",
"      Morbidity rates for extremely premature infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/44/39629\" title=\"table 3\">",
"      Neurodevelopmental outcome of extremely premature survivors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41591?source=related_link\">",
"      Clinical features and diagnosis of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42697?source=related_link\">",
"      Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34922?source=related_link\">",
"      Long-term neurodevelopmental outcome of premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=related_link\">",
"      Pathogenesis and clinical features of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33913?source=related_link\">",
"      Periventricular leukomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22068?source=related_link\">",
"      Postnatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=related_link\">",
"      Prenatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=related_link\">",
"      Retinopathy of prematurity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_1_27673="Management of psychiatric and psychologic disorders in patients with cancer";
var content_f27_1_27673=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of psychiatric and psychologic disorders in patients with cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/1/27673/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/1/27673/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/1/27673/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/1/27673/contributors\">",
"     Jonathan M Silver, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/1/27673/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/1/27673/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/1/27673/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 30, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cancer have a high rate of psychiatric comorbidity; approximately one-half exhibit emotional difficulties. The psychological complications generally take the form of adjustment disorder, depressed mood, anxiety, impoverished life satisfaction, or loss of self-esteem. The patients most at risk for depression and other psychiatric illness have advanced disease, a prior psychiatric history, poorly controlled pain, and other life stressors or losses.",
"   </p>",
"   <p>",
"    In addition to these psychiatric conditions, non-specific distress and anxiety are very common in cancer patients, in addition to formal psychiatric diagnoses. Distress is the summation of multiple psychological, social, and spiritual factors. If severe enough, distress can interfere with the patient's ability to deal effectively with the illness, its symptoms, and the complications of treatment.",
"   </p>",
"   <p>",
"    Specific issues regarding the management of psychiatric illness in patients with cancer are reviewed here. The diagnosis of these disorders is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31080?source=see_link\">",
"     \"Diagnosis of psychiatric and psychologic disorders in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADJUSTMENT DISORDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification and diagnosis of adjustment disorder is not straightforward, but is important since many of these patients will benefit from counseling. Physicians attempting to identify individuals who could benefit from counseling should focus upon a lack of patient flexibility [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Those who develop adjustment disorder may be more rigid in their thinking and determined to address their cancer-related problems in the same manner as they have for prior stressors. If the old coping and problem-solving strategies fail, the person may begin to exhibit depressed mood and anxiety associated with adjustment disorder. In contrast, patients who successfully adapt typically have a flexible style [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    People with adjustment disorder have positive outcomes when they are treated with brief psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/4\">",
"     4",
"    </a>",
"    ]. Early treatment using counselors, nurses, and other staff is helpful before the problem expands to the point of requiring more intensive care.",
"   </p>",
"   <p>",
"    Psychotherapy for adjustment disorder addresses cancer-related stressors directly by teaching enhanced coping skills, focusing upon immediate problems in living caused by the disease. Establishing social support networks and psychoeducation are also important [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Informal support groups and more formal group therapy are highly effective for improving quality of life and decreasing depression and anxiety symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF DEPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to physically healthy patients, depression in patients with cancer is best managed utilizing a combination of supportive psychotherapy, cognitive-behavioral techniques, and antidepressant medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Successful management usually requires a combination of pharmacologic and nonpharmacologic interventions. The success of a integrated model for managing depression in patients with malignant disease was shown in a randomized trial in which 200 outpatients with cancer and a prognosis &ge;6 months who had a major depressive disorder (as identified by screening) were randomly assigned to usual care or usual care in combination with an intervention by a specially trained cancer nurse at each center [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/9\">",
"     9",
"    </a>",
"    ]. For patients in the both arms, the primary care physician and oncologist were informed of the diagnosis of major depression, and advice offered as to choice of antidepressant drug, if requested. In addition, patients in the intervention group were offered a maximum of 10 one-on-one sessions with a specially trained oncology nurse over a three-month period. These sessions included education about depression and its treatment (including pharmacologic methods), and problem solving strategies to overcome feelings of helplessness. Progress was monitored by monthly telephone calls for three months after the intervention sessions ended.",
"   </p>",
"   <p>",
"    At three months, patients in the intervention group had a significantly lower mean Symptom Checklist-20 depression score, and significantly lower anxiety and fatigue scores. The treatment effect was sustained at 6 and 12 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychopharmacologic interventions are the mainstay of management for patients with moderate to severe levels of depression; antidepressants are safe and effective in this setting. These drugs can alleviate depressive affect, emotional lability, irritability, and social withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/10\">",
"     10",
"    </a>",
"    ]. Medication also may help increase an individual's ability to participate in rehabilitation services and improve overall functioning.",
"   </p>",
"   <p>",
"    A systematic review of randomized trials conducted exclusively in cancer patients suggested that drug therapy is well tolerated and useful in treating symptoms of depression [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/11\">",
"     11",
"    </a>",
"    ]. However, the trials were small and unable to distinguish between different pharmacologic approaches.",
"   </p>",
"   <p>",
"    Patients with early stage cancer are similar to the average individual who needs an antidepressant; they can be safely and effectively treated with selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) with similar dose titrations as the physically healthy population. In patients with more advanced disease and increased levels of physical distress, the pharmacologic management is more complex and challenging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Antidepressant selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selection of an antidepressant depends upon a number of factors. Among the considerations are [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The type of depressive symptoms",
"     </li>",
"     <li>",
"      Current medical problems",
"     </li>",
"     <li>",
"      Side effect profiles",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The depressed patient who is experiencing agitation or insomnia may benefit from the more sedating antidepressants (eg, TCAs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"     table 1",
"    </a>",
"    ). A better choice for patients with fatigue or psychomotor slowing would be compounds with the least sedating effects (eg, SSRIs, stimulants).",
"   </p>",
"   <p>",
"    A number of coexisting medical problems may influence antidepressant selection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In addition to their antidepressant action, the TCAs have analgesic properties and the ability to potentiate the effects of opioid analgesics. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link&amp;anchor=H19#H19\">",
"       \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Antidepressants'",
"      </a>",
"      .) Thus, patients who are experiencing pain, particularly neuropathic pain, may benefit from these agents alone or in combination with other drugs.",
"     </li>",
"     <li>",
"      Patients with cardiovascular disease and older patients should take drugs that cause the least orthostatic hypotension (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with slow intestinal motility or urinary retention, or with stomatitis secondary to chemotherapy or radiotherapy, should receive medications with the least anticholinergic effects (eg, SSRIs).",
"     </li>",
"     <li>",
"      Patients at risk for seizures or who may have a lower seizure threshold because of other medications are more safely treated with agents that will not exacerbate the problem (eg, neuroleptics). Virtually any antidepressant can have a small effect on lowering the seizure threshold. However,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      has been associated with the highest incidence of seizures and should be used cautiously in patients with CNS disease.",
"     </li>",
"     <li>",
"      Liquid formulations are available for some antidepressants (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"       doxepin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      ) and may be better options for patients who cannot swallow pills.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While attention to potentially upsetting or adverse effects of the different classes of antidepressants is warranted, many times side effects can be used to the patient's advantage (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"     table 1",
"    </a>",
"    ). As an example, sedation may be useful to the agitated patient who is anxious and cannot sleep, while the side effect of activation may be useful to the hypersomnolent, withdrawn patient with lethargy. In addition, some antidepressants stimulate appetite, a useful effect when appetite is decreased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Tricyclic antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;TCAs have been used frequently in the cancer setting (",
"    <a class=\"graphic graphic_table graphicRef53818 \" href=\"UTD.htm?24/43/25278\">",
"     table 2",
"    </a>",
"    ). The TCAs should be started at a low dose (10 to 25 mg at bedtime) and increased slowly by 10 to 25 mg increments every one to two days until a beneficial effect is achieved. This slow titration is especially important for debilitated patients with advanced disease. Patients with cancer may exhibit a therapeutic response to the TCAs at lower doses than physically healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/13\">",
"     13",
"    </a>",
"    ]. Serial plasma drug levels can be utilized to monitor the effective and safe administration of the drugs, minimizing the risk of side effects or toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/14\">",
"     14",
"    </a>",
"    ]. A cardiac history and electrocardiogram should be obtained prior to prescribing TCAs since these drugs can have an adverse effect on cardiac rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tertiary amines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    ) tend to sedate patients, stimulate appetite, and cause anticholinergic side effects (eg, dry mouth, blurred vision, constipation, nausea, urinary retention, and tachycardia). Their metabolites, the secondary amines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    ) are less sedating and less anticholinergic. Many times patients can tolerate secondary amines in higher doses, allowing for greater therapeutic benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Selective serotonin reuptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;SSRIs have become the most widely used antidepressants (",
"    <a class=\"graphic graphic_table graphicRef53818 \" href=\"UTD.htm?24/43/25278\">",
"     table 2",
"    </a>",
"    ). Their efficacy and side effect profiles in particular make them attractive agents for some patients with cancer. One study found that both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    led to improvements in depression, anxiety, and overall quality of life in depressed women with advanced cancer, and were well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/16\">",
"     16",
"    </a>",
"    ]. A larger double-blind study suggested that fluoxetine (20 mg daily) was superior to placebo in improving depression and overall quality of life in outpatients with advanced cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SSRIs cause fewer problems with cardiac arrhythmias, hypotension, and anticholinergic effects than the TCAs (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"     table 1",
"    </a>",
"    ). In addition, the SSRIs generally have less sedative, autonomic, and anticholinergic effects.",
"   </p>",
"   <p>",
"    The SSRIs may increase blood levels of other drugs by dislodging them from blood proteins. They also inhibit the cytochrome P450 isoenzymes. Thus, blood levels of any medications that are metabolized by the P450 system may be increased. This is an important consideration in the cancer population since many of these patients are on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or cisapride, two medications that are substrates for the P450 system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The other available antidepressants vary widely in their mechanism of action and side effects (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53818 \" href=\"UTD.htm?24/43/25278\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       Bupropion",
"      </a>",
"      is both an antidepressant and central nervous system stimulant that does not interact with other medications. It is very useful in depressed patients with psychomotor retardation and can be used in a wide variety of patients with few side effects. The drug is thought to act through the dopamine pathways, but its precise mechanism of action is not known. It cannot be used in patients who have a history of a seizure disorder and should be used with caution in patients with possible CNS disease that may be prone to seizures.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       Venlafaxine",
"      </a>",
"      is a mixed serotonin and norepinephrine reuptake inhibitor that is well tolerated by cancer patients. It is not significantly active at the cytochrome P450 system and is somewhat less protein bound than the other antidepressants. Venlafaxine has been associated with safe but uncomfortable withdrawal symptoms (anxiety, nausea, insomnia) at discontinuation, suggesting that the drug should be tapered rather than stopped abruptly.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       Mirtazapine",
"      </a>",
"      is an antidepressant with a novel mechanism of action. The cell receptors that regulate production of norepinephrine and serotonin are blocked so that the neurotransmitters continue to be produced even when their concentrations might normally shut down production by the cell. In addition, mirtazapine has 5HT2 and 5HT3 blocking action that may make it useful as a coanalgesic and antiemetic; clinical trials are underway to evaluate its potential in these two important areas for cancer patients. Mirtazapine also appears to block the H1 receptor in the CNS. It has some sedative side effects and stimulates appetite, side effects that may be very useful in some patients. It can be administered as a single dose at bedtime.",
"      <br/>",
"      <br/>",
"      One open label pilot study of mirtazapine (15 to 30 mg at bedtime) suggests that patients with advanced cancer may derive benefit from this drug with regard to mood, weight loss and insomnia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/18\">",
"       18",
"      </a>",
"      ]. Treatment was well-tolerated at either starting dose.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       Trazodone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"       nefazodone",
"      </a>",
"      are related antidepressants that are SSRIs in part, but also have some other actions. Trazodone is typically sedating and is used frequently to help with sleep disturbance. It can be associated with priapism. Nefazodone has blocking action at the 5HT2 receptor which may make it useful for patients with anxiety. It is an active inhibitor of the 3A4 isoenzyme and thus may increase the concentration of other medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Psychostimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The psychostimulants",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    are an alternative for depressed patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. These drugs improve attention, concentration, and overall performance on neurologic testing in the medically ill [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/21\">",
"     21",
"    </a>",
"    ]. Mood, appetite and sense of well being can be improved for the patient at the same time the medication is decreasing feelings of weakness and fatigue. An additional benefit of methylphenidate and dextroamphetamine is reduction of the sedation caused by opioid analgesics; they also provide adjuvant analgesia in patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/22\">",
"     22",
"    </a>",
"    ]. The psychostimulants may play a useful role in helping cancer patients feel energetic enough to engage in rehabilitation efforts until their energy level ultimately improves from the direct effects of such efforts.",
"   </p>",
"   <p>",
"    The starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    is 5 to 10 mg once or twice daily. Maximum doses may range as high as 60 mg per day. Typically patients are maintained on the stimulant for one to two months or longer. Tolerance can develop and dose adjustment may be necessary over time. Most patients respond quickly to these agents and, if taken in the morning and early afternoon, they should not interfere with sleep. Side effects include anxiety, overstimulation, headache, increase in blood pressure, and tremors; however, these are rarely a problem with the typically low doses used.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     Modafinil",
"    </a>",
"    , a benzhydryl sulfinyl acetamide non-amphetamine \"wake-promoting agent,\" was introduced to the world market in 1994 for the treatment of narcolepsy and idiopathic hypersomnia, and was approved for use in the United States in 1999. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4071?source=see_link\">",
"     \"Treatment of narcolepsy\"",
"    </a>",
"    .) Modafinil has not been directly compared with amphetamines in patients with narcolepsy, but early indications are that it is better tolerated and has less abuse potential. It is usually administered in a single morning dose of 100 or 200 mg.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     Modafinil",
"    </a>",
"    may be a useful treatment for fatigue, depression, and opioid-induced sedation, and is well tolerated. Although modafinil may offer similar benefit to the amphetamines in patients with cancer, no published studies are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=see_link\">",
"     \"Cancer-related fatigue: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Combined therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined antidepressant therapy may provide certain advantages in select patients, particularly those experiencing distressing physical symptoms. Patients with depression and severe fatigue or psychomotor slowing, for example, may gain the most from the use of TCAs, SSRIs, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    plus psychostimulants. Patients with depression and anxiety or insomnia may gain the most from the combination of TCAs and SSRIs, or an SSRI with mirtazapine.",
"   </p>",
"   <p>",
"    Many antidepressants require weeks to reach peak efficacy. Thus, augmentation with another medication directed at the most distressful symptom not only leads to a quicker benefit to the patient, but also may improve compliance. This symptom driven approach is particularly helpful in patients with advanced cancer in whom treatment is often complex, but immediate relief of symptom distress is a priority.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nonpharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cancer and depression are often reacting to the burden of the illness and the effect it has on their lives. Psychosocial interventions are used to help individuals, families, and groups. The general objective of this therapy is to improve coping skills through educational, behavioral, or psychodynamic approaches.",
"   </p>",
"   <p>",
"    The benefits of psychotherapy in patients with advanced incurable cancer were addressed in a Cochrane review [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/23\">",
"     23",
"    </a>",
"    ]. In six trials (292 patients in the psychotherapy arm, and 225 in the control arm), psychotherapy was associated with a significant decrease in depression score when compared to treatment as usual. However, there were no randomized trials that focused on psychotherapy in cancer patients with clinically diagnosed depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Crisis intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians working in oncology rely primarily upon short-term supportive psychotherapy based on a crisis intervention model to help patients with depressive symptomatology. Crisis intervention is a process of actively influencing psychosocial functioning during a period of disequilibrium. It is directed at alleviating the immediate impact of disruptive stressful events. The aim is to reduce emotional distress while working toward strengthening the patient's psychological and social resources. Crisis therapy is generally time limited and asserts clear-cut goals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Supportive/crisis",
"    </span>",
"    intervention psychotherapy involves clarifying information and answering questions about the illness and its treatment, correcting misunderstanding, and giving reassurance about the situation. Describing common reactions to illness may help the patient and family to normalize their experience. The patients' usual adaptive strategies should be explored and strengths supported as needed in adjustment. Patients are encouraged to discuss how they feel about their lifestyle modifications, family role changes, and fears of dependency and abandonment. Themes of loss and anticipatory grief are also explored. Patients often experience loss of good health, body integrity, and self-esteem, along with losses secondary to cancer (eg, financial, social, and occupational). Therapy seeks to improve a sense of control and morale. When the focus of treatment changes from cure to palliation, it is important for patients to know that they will not be abandoned and that their comfort, pain control, and dignity will receive continued attention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cognitive-behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive-behavioral techniques are often integrated into depression therapy and are very useful and effective. These approaches explore patients' beliefs about the cancer diagnosis and its treatment in order to elicit irrational or unhelpful thoughts that lead to feelings of helplessness and hopelessness. Therapy then leads to the correction of these maladaptive thoughts along with providing new coping skills (eg, relaxation). Both group and individual treatment are effective for reducing depressive symptoms and distress and improving quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/11,25,26\">",
"     11,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cognitive-behavioral interventions help patients allay exaggerated fears by encouraging them to consider different possible outcomes for their situation. Helping the patient focus upon aspects of the disease and its treatment that they have control over and encouraging behavior modification that will keep them involved and positive could provide a better quality of life.",
"   </p>",
"   <p>",
"    Relaxation techniques and imagery may enhance any of these therapeutic interventions. Simple focused breathing exercises, meditation, and progressive muscle relaxation can be used to lessen the episodic anxiety that many cancer patients experience. Pleasant imagery, such as visualizing a gentle stream flowing through a beautiful landscape, may also ease the tension that some patients feel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Support groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Support groups are important adjunctive intervention modalities for cancer patients and family members who are distressed. Hospitals and community organizations will often sponsor groups that are professionally run",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    self-help. The professionally run groups usually use educational, supportive, or cognitive-behavioral methods, while lay groups focus upon education, practical advice and modeling, and serve as a source of mutual support and advocacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ANXIETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of anxiety in patients with cancer involves the combination of psychotherapy and a range of anxiolytic medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    .) Pharmacotherapy in patients with more advanced illness includes the judicious use of benzodiazepines, neuroleptics, antihistamines, antidepressants, and opioid analgesics [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines are the mainstay of pharmacologic therapy for anxiety disorders. The shorter acting benzodiazepines such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"     oxazepam",
"    </a>",
"    , are safest in patients with cancer since they are least likely to lead to toxic accumulation due to impaired metabolism in debilitated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/29\">",
"     29",
"    </a>",
"    ]. Lorazepam and oxazepam are metabolized by conjugation in the liver and are therefore the safest choice in patients with hepatic disease.",
"   </p>",
"   <p>",
"    The disadvantage of using short-acting benzodiazepines is that patients often experience breakthrough anxiety or end of dose failure. Such patients may benefit from switching to longer acting benzodiazepines such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    ; we have found clonazepam to be particularly useful in this setting. We also frequently switch patients from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    to clonazepam when attempting to taper off the former. Clonazepam may have additional uses in patients with organic mood disorders who have symptoms of mania, and as an adjuvant analgesic in patients with neuropathic pain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fears of causing respiratory depression should not prevent the clinician from using adequate doses of benzodiazepines to control anxiety. The likelihood of respiratory depression is minimized with shorter acting drugs and small dose increments; ultimately the switch can be made to longer acting drugs. Common dosage regimens include:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    0.5 mg to 2.0 mg PO, IV or IM, every three to six hours;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    0.25 mg to 1.0 mg PO, three to four times daily;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    2.5 mg to 10 mg PO, PR, IM, or IV every 3 to 6 hours;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    1 to 2 mg PO, two to three times daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other anxiolytics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroleptics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    are useful in the treatment of anxiety when benzodiazepines are not sufficient for symptom control [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/28\">",
"     28",
"    </a>",
"    ]. They are also indicated when an organic etiology is suspected or when psychotic symptoms such as delusions or hallucinations accompany anxiety. Neuroleptics are probably the safest class of anxiolytics in patients for whom there is a legitimate concern of respiratory depression or compromise.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     Haloperidol",
"    </a>",
"    0.5 mg to 5 mg PO, IV, or SC every 2 to 12 hours, typically is sufficient to control anxious symptoms and avoid excessive sedation. Low potency neuroleptics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    (10 mg to 25 mg PO three times daily) also are effective anxiolytics and can help with insomnia and agitation.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4535?source=see_link\">",
"     Methotrimeprazine",
"    </a>",
"    (10 mg to 20 mg every four to eight hours, IM, IV, or SC) is a phenothiazine with unique analgesic and anxiolytic properties that is often used for the treatment of pain and anxiety in patients with advanced cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Its side effects include sedation, anticholinergic symptoms, and hypotension. Intravenous administration by slow infusion is preferable to avoid problems with hypotension.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     Chlorpromazine",
"    </a>",
"    (12.5 mg to 50 mg PO, IM or IV, every 4 to 12 hours) has similar side effects to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4535?source=see_link\">",
"     methotrimeprazine",
"    </a>",
"    that often limit its application in patients with cancer. However, it can be useful in patients in whom sedation is desirable. This class of drugs is associated with extrapyramidal side effects (particularly when patients are taking additional neuroleptics for antiemetic purposes) and the remote possibility of neuroleptic malignant syndrome. Tardive dyskinesia is rarely a concern given the generally short-term use and low doses employed in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     Hydroxyzine",
"    </a>",
"    is an antihistamine with mild anxiolytic, sedative, and analgesic properties. It is particularly useful when treating anxious cancer patients with pain. A dose of 100 mg administered parenterally has analgesic potency equivalent to 8 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , and also potentiates the analgesic effects of morphine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/35\">",
"     35",
"    </a>",
"    ]. As an anxiolytic, 25 mg to 50 mg of hydroxyzine every four to six hours PO, IV, or SC is effective.",
"   </p>",
"   <p>",
"    The atypical antipsychotics are useful in the treatment of both \"functional\" and \"organic\" anxiety syndromes, especially in older",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frail patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=see_link\">",
"     \"Prevention and treatment of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although not extensively studied in patients with cancer, anecdotal experience suggests that low doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    are effective and well-tolerated for the treatment of delirium and organic mental phenomena in patients with cancer, improving anxiety related to confusional states, delusions, and nausea [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In addition, they offer the advantage of not causing extrapyramidal symptoms in the doses generally used, ranging from 2.5 to 10 mg of olanzapine one to two times daily, and for risperidone, 0.5 to 4.0 mg one to two times daily.",
"   </p>",
"   <p>",
"    TCAs, SSRIs, and heterocyclic antidepressants are the most effective treatment for anxiety accompanying depression and also are helpful in treating panic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    .) Guidelines for their use are discussed in the section on depression above.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"     Buspirone",
"    </a>",
"    is a non-benzodiazepine anxiolytic that is useful along with psychotherapy in patients with chronic anxiety or anxiety related to adjustment disorders. The onset of anxiolytic action is delayed in comparison with the benzodiazepines, taking 5 to 10 days for relief of anxiety to begin. Buspirone is not a benzodiazepine; thus, it will not block benzodiazepine withdrawal, and caution must be used when switching from a benzodiazepine to this drug. The effective dose of buspirone is 10 mg PO three times daily [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/40\">",
"     40",
"    </a>",
"    ]. Its delayed onset of action and indication for use in chronic anxiety states limit its usefulness in patients with cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Nonpharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic interventions for anxiety and distress include supportive psychotherapy and behavioral interventions used alone or in combination. Brief supportive psychotherapy is often useful in dealing with both crisis-related issues as well as existential issues [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/41\">",
"     41",
"    </a>",
"    ]. Psychotherapeutic interventions can include both the patient and family, particularly as the patient with cancer becomes increasingly debilitated and less able to interact.",
"   </p>",
"   <p>",
"    The goals of psychotherapy for the anxious patient are to establish a bond that decreases the sense of isolation, to help the patient face cancer with a sense of integrity and self worth, to correct misconceptions about the past and present, to integrate the present illness into a continuum of life experiences, and to explore issues of separation, loss, and the unknown that lies ahead. As in the treatment of depression, the therapist should emphasize past strengths and support previously successful ways of coping. This helps the patient mobilize inner resources, modify plans for the future, and perhaps even accept the inevitability of death.",
"   </p>",
"   <p>",
"    Relaxation, guided imagery, and hypnosis may help reduce anxiety and thereby increase the patient's sense of control. Most patients with cancer, even those with advanced disease, are candidates for behavioral techniques despite physical debilitation. In assessing the utility of such interventions for a given patient, the clinician should take into account the patient's mental clarity. Confusional states interfere dramatically with the ability to focus attention and thereby limit the usefulness of these techniques, although occasionally they can be modified to include the mildly cognitively impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/42\">",
"     42",
"    </a>",
"    ]. This often involves the therapist taking a more active role by orienting the patient, creating a safe and secure environment, and evoking a conditioned response to the therapist's voice or presence.",
"   </p>",
"   <p>",
"    A typical behavioral intervention for anxiety includes a relaxation exercise combined with some distraction or imagery technique. The patient is first taught to relax with passive breathing accompanied by either passive or active muscle relaxation. Once in a relaxed state, the patient is taught a pleasant, distracting imagery exercise. In a randomized study comparing a relaxation technique with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    in the treatment of anxiety and distress in cancer patients, both treatments were effective for mild to moderate degrees of anxiety or distress [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/43\">",
"     43",
"    </a>",
"    ]. Alprazolam was more effective for greater levels of distress or anxiety and had a more rapid onset of beneficial effect. Relaxation techniques can be used in combination with anxiolytic medications for highly anxious patients.",
"   </p>",
"   <p>",
"    Stress management training has been recommended to relieve psychological distress during treatment, but has given conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In a trial of large patients (n = 382) about to begin chemotherapy, clinician-administered stress management training was not effective compared to usual care, whereas self-administered training was found to be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/44\">",
"     44",
"    </a>",
"    ]. In contrast, a previous trial of patients (n = 310) receiving radiation therapy found that self-administered training did not relieve psychological distress compared to usual care, except in those cases with the highest levels of initial psychosocial distress [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DELIRIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard approach for managing delirium in the cancer patient includes a search for underlying causes, correction of those factors, and management of symptoms. Symptomatic and supportive therapies also are important [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/46\">",
"     46",
"    </a>",
"    ], and fluid and electrolyte balance, nutrition, and vitamins may be helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=see_link\">",
"     \"Prevention and treatment of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measures to help reduce anxiety and disorientation include a quiet, well-lit room with familiar objects, a visible clock or calendar, and the presence of family. Judicious use of physical restraints, along with one-to-one nursing observation may be necessary. When supportive techniques alone are not effective, symptomatic treatment with neuroleptic or sedative medications are necessary. Sedation may be required to relieve severe agitation or insomnia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     Haloperidol",
"    </a>",
"    is the drug of choice for treatment of delirium in the medically ill [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Low doses (1 to 3 mg) are usually effective for agitation, paranoia, and fear. Typically 0.5 mg to 1.0 mg haloperidol (PO, IV, IM, SC) is administered, with repeat doses every 45 to 60 minutes titrated against symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/42,49\">",
"     42,49",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    0.5 mg to 1.0 mg every one to two hours PO or IV, plus haloperidol, may be more effective than the latter alone in rapidly sedating the agitated delirious patient. In a double-blind, randomized trial of haloperidol versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    versus lorazepam, lorazepam alone, in doses up to 8 mg in a 12 hour period, was ineffective in the treatment of delirium and contributed to worsening delirium and cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/48\">",
"     48",
"    </a>",
"    ]. Both neuroleptic drugs however, in low doses (approximately 2 mg of haloperidol",
"    <span class=\"nowrap\">",
"     equivalent/per",
"    </span>",
"    24 hours), were highly effective in controlling the symptoms of delirium and improving cognitive function. The atypical antipsychotics may have an as yet under-appreciated role in the management of cognitive disorders in cancer patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delirium during treatment for malignancy has been associated with an adverse outcome. In patients undergoing hematopoietic stem cell transplantation, those who have experienced delirium have significantly worse symptoms of depression, fatigue, and anxiety at 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/50\">",
"     50",
"    </a>",
"    ]. These signs and symptoms persisted at 80 days, including multiple impairment of neurocognitive function. Delirium may also be more frequent in patients with more severe disease, and at least two studies found that cancer patients experiencing delirium have an increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27673/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/57/11155?source=see_link\">",
"       \"Patient information: Delirium (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9800440\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer patients with adjustment disorder may respond to brief psychotherapy that addresses cancer-related stressors by teaching coping skills and focusing upon immediate problems. Psychoeducation and social support are also important, and informal support groups and formal group therapy are effective for improving quality of life and decreasing symptoms of depression and anxiety. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Adjustment disorder'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Successful treatment of depression or anxiety in cancer patients often requires a combination of pharmacologic and nonpharmacologic interventions. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Management of depression'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Anxiety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many antidepressants are available to treat patients with cancer (",
"      <a class=\"graphic graphic_table graphicRef53818 \" href=\"UTD.htm?24/43/25278\">",
"       table 2",
"      </a>",
"      ). The choice depends upon a several factors, including specific depressive symptoms, comorbid medical problems, and side effect profiles (",
"      <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"       table 1",
"      </a>",
"      ). As an example, patients with agitation or insomnia may benefit from more sedating antidepressants (eg, tricyclics,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      ). By contrast, a better choice for patients with fatigue or psychomotor slowing may be a less sedating drug (eg, SSRIs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Antidepressant selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The psychostimulants",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"       dextroamphetamine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"       modafinil",
"      </a>",
"      are an option for depressed patients with cancer, either as monotherapy or adjunctive treatment with an antidepressant. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Psychostimulants'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Combined therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonpharmacologic interventions for depressed cancer patients include crisis intervention, cognitive-behavioral therapy (CBT), and support groups. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Nonpharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mainstay of pharmacotherapy for anxiety disorders in cancer patients is a benzodiazepine. Shorter acting drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"       alprazolam",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"       oxazepam",
"      </a>",
"      ) are safest, but often lead to breakthrough anxiety or end of dose failure. Thus, some patients may benefit from longer acting benzodiazepines such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Benzodiazepines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For cancer patients with anxiety that does not respond to a benzodiazepine, other options include antipsychotics, antihistamines (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"       hydroxyzine",
"      </a>",
"      ), and antidepressants. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Other anxiolytics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonpharmacologic interventions for cancer patients with anxiety include supportive psychotherapy and behavioral interventions (eg, relaxation and guided imagery). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Nonpharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The standard approach for managing delirious cancer patients includes determining and correcting underlying causes, and management of symptoms. Low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      is effective for treatment of delirium that includes agitation, paranoia, and fear. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Delirium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We encourage clinicians to print or e-mail the patient information topic about delirium. (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/57/11155?source=see_link\">",
"       \"Patient information: Delirium (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/1\">",
"      Carson DK, Council JR, Volk MA. Temperament as a predictor of psychological adjustment in female adult incest victims. J Clin Psychol 1989; 45:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/2\">",
"      Rogers S, LeUnes A. A psychometric and behavioral comparison of delinquents who were abused as children with their non-abused peers. J Clin Psychol 1979; 35:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/3\">",
"      Lee RE. Returning to work: potential problems for mid-career mothers. J Sex Marital Ther 1983; 9:219.",
"     </a>",
"    </li>",
"    <li>",
"     Sifneos, P. Brief dynamic and crisis therapy. In: Comprehensive Textbook of Psychiatry, vol. 2, 5th ed, Kaplan, H, Sadock, B (Eds), Williams and Wilkins, Baltimore 1989. p.1562.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/5\">",
"      Pollin IS. Model curriculum in Medical Crisis Counseling. Linda Pollin Foundation/NIMH Workshop. Gen Hosp Psychiatry 1992; 14:11S.",
"     </a>",
"    </li>",
"    <li>",
"     Wise, M. Adjustment disorders and impulse disorders not otherwise classified. In: The American Psychiatric Press Textbook of Psychiatry, 2nd ed, Talbot, J, Hales, R, Yudofsky, S (Eds), American Psychiatric Press, Washington, DC 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/7\">",
"      Spiegel D, Bloom JR, Yalom I. Group support for patients with metastatic cancer. A randomized outcome study. Arch Gen Psychiatry 1981; 38:527.",
"     </a>",
"    </li>",
"    <li>",
"     Zabora, J. Screening procedures for psychosocial distress. In: Psycho-oncology, Holland, J (Ed), Oxford University Press, New York 1998. p.653.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/9\">",
"      Strong V, Waters R, Hibberd C, et al. Management of depression for people with cancer (SMaRT oncology 1): a randomised trial. Lancet 2008; 372:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/10\">",
"      Marmelstein, H, Lesko, L, Holland, JC. Depression in the cancer patient. J Psychooncology 1992; 1:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/11\">",
"      Williams S, Dale J. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer 2006; 94:372.",
"     </a>",
"    </li>",
"    <li>",
"     Stoudemire, A, Fogel, BS, Gulley, LR. Psychopharmacology in the medically ill, In: Medical psychiatric practice, Stoudemire, A, Fogel, BS (Eds), American Psychiatric Press, Washington, DC, 1991. p.31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/13\">",
"      Massie MJ, Gagnon P, Holland JC. Depression and suicide in patients with cancer. J Pain Symptom Manage 1994; 9:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/14\">",
"      Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol 1990; 10:88.",
"     </a>",
"    </li>",
"    <li>",
"     Roose, S, Glassman, A. Cardiovascular effects of tricyclic antidepressants in depressed patients. J Clin Psychiatry Monograph Series 7, 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/16\">",
"      Holland JC, Romano SJ, Heiligenstein JH, et al. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology 1998; 7:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/17\">",
"      Fisch MJ, Loehrer PJ, Kristeller J, et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol 2003; 21:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/18\">",
"      Theobald DE, Kirsh KL, Holtsclaw E, et al. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 2002; 23:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/19\">",
"      Kaufmann MW, Murray GB, Cassem NH. Use of psychostimulants in medically ill depressed patients. Psychosomatics 1982; 23:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/20\">",
"      Fernandez F, Adams F, Holmes VF, et al. Methylphenidate for depressive disorders in cancer patients. An alternative to standard antidepressants. Psychosomatics 1987; 28:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/21\">",
"      Fernandez F, Adams F, Levy JK, et al. Cognitive impairment due to AIDS-related complex and its response to psychostimulants. Psychosomatics 1988; 29:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/22\">",
"      Bruera E, Chadwick S, Brenneis C, et al. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep 1987; 71:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/23\">",
"      Akechi T, Okuyama T, Onishi J, et al. Psychotherapy for depression among incurable cancer patients. Cochrane Database Syst Rev 2008; :CD005537.",
"     </a>",
"    </li>",
"    <li>",
"     Parad, HJ, Parad, LG. Crisis Intervention: An introductory overview. In: Crisis Intervention: The practitioner's sourcebook for brief therapy, Parad, HJ, Parad, LG (Eds), Family Service America, Wisconsin 1990. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/25\">",
"      Fawzy FI, Cousins N, Fawzy NW, et al. A structured psychiatric intervention for cancer patients. I. Changes over time in methods of coping and affective disturbance. Arch Gen Psychiatry 1990; 47:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/26\">",
"      Spiegel D, Bloom JR, Kraemer HC, Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 1989; 2:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/27\">",
"      Holland JC. Anxiety and cancer: the patient and the family. J Clin Psychiatry 1989; 50 Suppl:20.",
"     </a>",
"    </li>",
"    <li>",
"     Massie, MJ. Anxiety, panic and phobias. In: Handbook of Psychooncology: Psychological care of the patient with cancer, Holland, JC, Rowland, J (Eds), Oxford University Press, New York 1989. p.300.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/29\">",
"      Hollister LE. Pharmacotherapeutic considerations in anxiety disorders. J Clin Psychiatry 1986; 47 Suppl:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/30\">",
"      Chouinard G, Young SN, Annable L. Antimanic effect of clonazepam. Biol Psychiatry 1983; 18:451.",
"     </a>",
"    </li>",
"    <li>",
"     Walsh, TD. Adjuvant analgesic therapy in cancer pain. In: Advances in Pain Research and Therapy, vol. 16, Second International Congress on Cancer Pain, Foley, KM, Bonica, JJ, Ventafridda, V (Eds), Raven Press, New York 1990. p.155.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/32\">",
"      Beaver WT, Wallenstein SL, Houde RW, Rogers A. A comparison of the analgesic effects of methotrimeprazine and morphine in patients with cancer. Clin Pharmacol Ther 1966; 7:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/33\">",
"      Oliver DJ. The use of methotrimeprazine in terminal care. Br J Clin Pract 1985; 39:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/34\">",
"      Breitbart W. Tardive dyskinesia associated with high-dose intravenous metoclopramide. N Engl J Med 1986; 315:518.",
"     </a>",
"    </li>",
"    <li>",
"     Beaver, WT, Feise, G. Comparison of the analgesic effects of morphine, hydroxyzine and their combination in patients with post-operative pain. In: Advances in Pain Research and Therapy, Bonica, JJ, Albe-Fessard (Eds), Raven Press, New York 1976. p.553.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/36\">",
"      Passik SD, Dugan W, McDonald MV, et al. Oncologists' recognition of depression in their patients with cancer. J Clin Oncol 1998; 16:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/37\">",
"      Passik SD, Cooper M. Complicated delirium in a cancer patient successfully treated with olanzapine. J Pain Symptom Manage 1999; 17:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/38\">",
"      Liebowitz MR. Imipramine in the treatment of panic disorder and its complications. Psychiatr Clin North Am 1985; 8:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/39\">",
"      Popkin MK, Callies AL, Mackenzie TB. The outcome of antidepressant use in the medically ill. Arch Gen Psychiatry 1985; 42:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/40\">",
"      Robinson D, Napoliello MJ, Schenk J. The safety and usefulness of buspirone as an anxiolytic drug in elderly versus young patients. Clin Ther 1988; 10:740.",
"     </a>",
"    </li>",
"    <li>",
"     Massie MJ, Holland JC, Straker N. Psychotherapeutic interventions. In: Handbook of Psychooncology: Psychological Care of the Patient with Cancer, Holland JC, Rowland JH (Eds), Oxford University Press, New York 1989. p.455.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/42\">",
"      Breitbart W. Psychiatric management of cancer pain. Cancer 1989; 63:2336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/43\">",
"      Holland JC, Morrow GR, Schmale A, et al. A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. J Clin Oncol 1991; 9:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/44\">",
"      Jacobsen PB, Meade CD, Stein KD, et al. Efficacy and costs of two forms of stress management training for cancer patients undergoing chemotherapy. J Clin Oncol 2002; 20:2851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/45\">",
"      Krischer MM, Xu P, Meade CD, Jacobsen PB. Self-administered stress management training in patients undergoing radiotherapy. J Clin Oncol 2007; 25:4657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/46\">",
"      Lipowski ZJ. Delirium (acute confusional states). JAMA 1987; 258:1789.",
"     </a>",
"    </li>",
"    <li>",
"     Murray, GB. Confusion, delirium, and dementia. In: Massachusetts General Hospital Handbook of General Hospital Psychiatry, 2nd ed, Hackett, T, Cassem, NH (Eds), PSG Publishing Company, Littleton, MA 1987. p.84.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/48\">",
"      Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/49\">",
"      Massie MJ, Holland J, Glass E. Delirium in terminally ill cancer patients. Am J Psychiatry 1983; 140:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/50\">",
"      Fann JR, Alfano CM, Roth-Roemer S, et al. Impact of delirium on cognition, distress, and health-related quality of life after hematopoietic stem-cell transplantation. J Clin Oncol 2007; 25:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/51\">",
"      Caraceni A, Nanni O, Maltoni M, et al. Impact of delirium on the short term prognosis of advanced cancer patients. Italian Multicenter Study Group on Palliative Care. Cancer 2000; 89:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27673/abstract/52\">",
"      Lawlor PG, Gagnon B, Mancini IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med 2000; 160:786.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4853 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-DF5911362B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_1_27673=[""].join("\n");
var outline_f27_1_27673=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9800440\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADJUSTMENT DISORDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MANAGEMENT OF DEPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Antidepressant selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Tricyclic antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Selective serotonin reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Psychostimulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Combined therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Crisis intervention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cognitive-behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Support groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ANXIETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other anxiolytics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DELIRIUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9800440\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/4853\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/4853|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/46/38639\" title=\"table 1\">",
"      Side effects antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/43/25278\" title=\"table 2\">",
"      Pharmacology antidepressants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=related_link\">",
"      Cancer-related fatigue: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31080?source=related_link\">",
"      Diagnosis of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/57/11155?source=related_link\">",
"      Patient information: Delirium (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=related_link\">",
"      Prevention and treatment of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4071?source=related_link\">",
"      Treatment of narcolepsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_1_27674="Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month";
var content_f27_1_27674=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/1/27674/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/1/27674/contributors\">",
"     Nader Shaikh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/1/27674/contributors\">",
"     Alejandro Hoberman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/1/27674/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/1/27674/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/1/27674/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/1/27674/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/1/27674/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/1/27674/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract infections (UTI) are a common and important clinical problem in childhood. Upper urinary tract infections (ie, acute pyelonephritis) may lead to renal scarring, hypertension, and end-stage renal dysfunction. Although children with pyelonephritis tend to present with fever, it can be difficult on clinical grounds to distinguish cystitis from pyelonephritis, particularly in young children (those younger than two years) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, we have defined UTI broadly here without attempting to distinguish cystitis from pyelonephritis. Acute cystitis in older children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42937?source=see_link\">",
"     \"Acute cystitis in children older than two years and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The acute management and prognosis of UTI in children will be reviewed here. The epidemiology, risk factors, clinical features, diagnosis, long-term management, and prevention of UTI in children and UTI in newborns are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26360?source=see_link\">",
"     \"Epidemiology and risk factors for urinary tract infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=see_link\">",
"     \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7606?source=see_link\">",
"     \"Long-term management and prevention of urinary tract infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14264?source=see_link\">",
"     \"Urinary tract infections in newborns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treatment for urinary tract infections (UTI) include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elimination of infection and prevention of urosepsis",
"     </li>",
"     <li>",
"      Prevention of recurrence and long-term complications including hypertension, renal scarring, and impaired renal growth and function",
"     </li>",
"     <li>",
"      Relief of acute symptoms (eg, fever, dysuria, frequency)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute management of UTI in children consists of antimicrobial therapy to treat the acute infection and evaluation for possible predisposing factors (eg, urologic abnormalities). Long-term management centers on prevention of recurrence and complications; it is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7606?source=see_link\">",
"     \"Long-term management and prevention of urinary tract infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Decision to hospitalize",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most infants older than two months with UTI can be safely managed as outpatients as long as close follow-up is possible [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Usual indications for hospitalization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parenteral therapy include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &lt;2 months",
"     </li>",
"     <li>",
"      Clinical urosepsis (eg, toxic appearance, hypotension, poor capillary refill)",
"     </li>",
"     <li>",
"      Immunocompromised patient",
"     </li>",
"     <li>",
"      Vomiting or inability to tolerate oral medication",
"     </li>",
"     <li>",
"      Lack of adequate outpatient follow-up (eg, no telephone, live far from hospital, etc)",
"     </li>",
"     <li>",
"      Failure to respond to outpatient therapy (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Response to therapy'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of antimicrobial therapy for urinary tract infections (UTI) is demonstrated by the change in mortality between the pre- and post-antibiotic eras. The mortality of UTI was as high as 20 percent in the preantibiotic era. In contrast, when UTI are appropriately treated with antibiotics, acute complications (eg, renal abscess, death) are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Antimicrobial therapy for children with presumed UTI depends upon a number of factors, including the age of the child, severity of illness, presence of vomiting, duration of fever before presentation, underlying medical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urologic problems, and the antimicrobial resistance patterns in the community.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early and aggressive antibiotic therapy (eg, within 72 hours of presentation) is necessary to prevent renal damage. Delayed therapy has been associated with increased severity of infection and greater likelihood of renal damage in experimental, retrospective, prospective, and small randomized studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/8-14\">",
"     8-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decisions regarding the initiation of empiric antimicrobial therapy for UTI are best made on a case-by-case basis based upon the probability of UTI, which is determined by demographic and clinical factors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that empiric antimicrobial therapy be initiated immediately after appropriate urine collection in children with suspected UTI and a positive urinalysis. This is particularly true for children who are at increased risk for renal scarring if UTI is not promptly treated, including children who present with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever (especially &gt;39&deg;C [102.2&deg;F] or &gt;48 hours)",
"     </li>",
"     <li>",
"      Ill appearance",
"     </li>",
"     <li>",
"      Costovertebral angle tenderness",
"     </li>",
"     <li>",
"      Known immune deficiency",
"     </li>",
"     <li>",
"      Known urologic abnormality",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Gram-stained smear of the urine, if readily available, can help guide decisions regarding empiric therapy. The ultimate choice of antimicrobial therapy is based upon the susceptibilities of the organism isolated.",
"   </p>",
"   <p>",
"    <em>",
"     Escherichia coli",
"    </em>",
"    is the most common bacterial cause of UTI; it accounts for approximately 80 percent of UTI in children. Other gram-negative bacterial pathogens include",
"    <em>",
"     Klebsiella",
"    </em>",
"    ,",
"    <em>",
"     Proteus",
"    </em>",
"    ,",
"    <em>",
"     Enterobacter",
"    </em>",
"    , and",
"    <em>",
"     Citrobacter",
"    </em>",
"    . Gram-positive bacterial pathogens include",
"    <em>",
"     Staphylococcus saprophyticus",
"    </em>",
"    ,",
"    <em>",
"     Enterococcus",
"    </em>",
"    , and, rarely,",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26360?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and risk factors for urinary tract infections in children\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend that empiric therapy for UTI in infants and children include an antibiotic that provides adequate coverage for",
"    <em>",
"     E. coli",
"    </em>",
"    . The agent of choice should be guided by local resistance patterns.",
"   </p>",
"   <p>",
"    Approximately 50 percent of",
"    <em>",
"     E. coli",
"    </em>",
"    are resistant to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. In addition, increasing rates of",
"    <em>",
"     E. coli",
"    </em>",
"    resistance to first-generation cephalosporins (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/5/30804?source=see_link\">",
"     cephalexin",
"    </a>",
"    ),",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/3/29750?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) have been reported in some communities [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/16-21\">",
"     16-21",
"    </a>",
"    ]. Increased resistance to extended-spectrum cephalosporins (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"     cefepime",
"    </a>",
"    ), has been reported in children receiving prophylactic antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Recent antibiotic exposure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Third-generation cephalosporins (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/18/25892?source=see_link\">",
"     cefpodoxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/32/38404?source=see_link\">",
"     cefixime",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/2/6181?source=see_link\">",
"     cefdinir",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/44/24260?source=see_link\">",
"     ceftibuten",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ) and aminoglycosides (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"     amikacin",
"    </a>",
"    ) are appropriate first-line agents for empiric treatment of UTI in children. However, these drugs are not effective in treating",
"    <em>",
"     Enterococcus",
"    </em>",
"    and should not be used as monotherapy for patients in whom enterococcal UTI is suspected (eg, those with a urinary catheter in place, instrumentation of the urinary tract, or an anatomical abnormality). In such patients,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    should be added. Hydration status and renal function should be assessed in patients who are treated with aminoglycosides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children older than two months of age who are not vomiting can be treated with orally administered antimicrobials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/3,24\">",
"     3,24",
"    </a>",
"    ]. Close contact with the family should be maintained for the first two to three days of therapy; the seriousness of the infection and the need for completion of the entire course of therapy should be stressed.",
"   </p>",
"   <p>",
"    We suggest a third-generation cephalosporin (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/32/38404?source=see_link\">",
"     cefixime",
"    </a>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/2/6181?source=see_link\">",
"     cefdinir",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/44/24260?source=see_link\">",
"     ceftibuten",
"    </a>",
"    ) as the first-line oral agent in the treatment of UTI in children without genitourinary abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/4,5,25,26\">",
"     4,5,25,26",
"    </a>",
"    ]. In a randomized, controlled trial of 306 children 1 to 24 months of age with a febrile UTI, oral therapy with cefixime for 14 days was as effective as intravenous therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    for three days followed by oral therapy with cefixime [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/4\">",
"     4",
"    </a>",
"    ]. The rates of symptom resolution (mean time to defervescence approximately 24 hours), sterilization of the urine (100 percent), reinfection (4.6 and 7.2 percent), and renal scarring at six months (9.8 and 7.2 percent) did not differ between groups.",
"   </p>",
"   <p>",
"    A similar trial in children 6 months to 16 years, albeit limited by imbalances in treatment group comparability at baseline and high drop-out rates, found once-daily therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/44/24260?source=see_link\">",
"     ceftibuten",
"    </a>",
"    to be comparable to initial therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    followed by ceftibuten [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/25\">",
"     25",
"    </a>",
"    ]. Oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three divided doses) also was shown to be as effective as parenteral therapy followed by oral therapy in a multicenter, randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/27\">",
"     27",
"    </a>",
"    ]. However,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    -clavulanate is associated with increasing rates of resistance. In a child with a penicillin and cephalosporin allergy, treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX), or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38128?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (if the local resistance rates to TMP-SMX are known to be high) and close follow-up of the antimicrobial sensitivity results is a reasonable strategy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/32/38404?source=see_link\">",
"     Cefixime",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/2/6181?source=see_link\">",
"     cefdinir",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/44/24260?source=see_link\">",
"     ceftibuten",
"    </a>",
"    are dosed as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/32/38404?source=see_link\">",
"       Cefixime",
"      </a>",
"      (16",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      by mouth on the first day, followed by 8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily to complete therapy) (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Duration of therapy'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/2/6181?source=see_link\">",
"       Cefdinir",
"      </a>",
"      (14",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      by mouth once daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/44/24260?source=see_link\">",
"       Ceftibuten",
"      </a>",
"      (9",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      by mouth once daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other third-generation cephalosporins that may be used for oral therapy include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/18/25892?source=see_link\">",
"     cefpodoxime",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/3\">",
"     3",
"    </a>",
"    ]. However, no large trials have specifically examined the efficacy of these agents for pediatric UTI.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     Amoxicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    are not routinely recommended for empiric therapy because of the high rate of resistance of",
"    <em>",
"     E. coli",
"    </em>",
"    . Similarly,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    , first-generation cephalosporins (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/5/30804?source=see_link\">",
"     cephalexin",
"    </a>",
"    ), and TMP-SMX should be used with caution because of the increasing rates of resistance to these drugs in some communities.",
"   </p>",
"   <p>",
"    Fluoroquinolones (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38128?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ) are effective for",
"    <em>",
"     E. coli",
"    </em>",
"    , and resistance is rare. However, the safety of quinolones in children is still under study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, the widespread use of fluoroquinolones is leading to increased resistance among other bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Ciprofloxacin should not be used as a first-line agent. The American Academy of Pediatrics (AAP) Committee on Infectious Diseases recommends that the use of ciprofloxacin for UTI in children be limited to UTI caused by",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    or other multidrug-resistant, gram-negative bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral agents that are excreted in the urine but do not achieve therapeutic serum (eg, nalidixic acid,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/21/10581?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    ) should not be used to treat UTI in febrile infants and young children in whom renal involvement is likely because parenchymal and serum concentrations may be insufficient to treat pyelonephritis or urosepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Parenteral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Third- or fourth-generation cephalosporins (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"     cefepime",
"    </a>",
"    ) and aminoglycosides (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    ) are appropriate first-line parenteral agents for empiric treatment of UTI in children. Definitive therapy is based upon the results of urine culture and sensitivities.",
"   </p>",
"   <p>",
"    Acceptable inpatient treatment regimens include the combination of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    ; gentamicin alone; or a third- or fourth-generation cephalosporin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/7,32,33\">",
"     7,32,33",
"    </a>",
"    ]. Ampicillin should be included if enterococcal UTI is suspected. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Recent antibiotic exposure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The doses are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/3,34\">",
"     3,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       Ampicillin",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      IV divided in four doses)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"       Gentamicin",
"      </a>",
"      (7.5",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      IV divided in three doses)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       Cefotaxime",
"      </a>",
"      (150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV divided in three or four doses)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"       Cefepime",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided in two doses for children weighing &le;40 kg, maximum daily dose 1 g; 500 mg twice per day for children weighing &gt;40 kg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Parenteral antibiotics should be continued until the patient is clinically improved (eg, afebrile) and able to tolerate oral liquids and medications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65841353\">",
"    <span class=\"h4\">",
"     Outpatient parenteral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once-daily parenteral administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    in a day treatment center may avoid the need for hospital admission in select patients (eg, children who are &ge;3 months old who are unable to tolerate oral therapy and are nontoxic appearing, well hydrated, without urologic abnormalities, and whose caretakers will be able to adhere to the outpatient regimen) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Recent antibiotic exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recent exposure to antibiotics, whether for treatment of an infection or as antimicrobial prophylaxis, is an important consideration in the choice of empiric antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/22,23,38,39\">",
"     22,23,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624406996\">",
"    <span class=\"h3\">",
"     Recurrent UTI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Review of the antimicrobial susceptibilities of the most recent urinary pathogens can be helpful in choosing empiric therapy for children with recurrent UTI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a systematic review, short course antimicrobial therapy (two to four days) was as effective as standard duration (7 to 14 days) therapy in eradicating bacteria in children with suspected lower urinary tract infection (ie, afebrile children) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/40\">",
"     40",
"    </a>",
"    ]. However, there are few data to guide duration of antimicrobial therapy in children with febrile UTIs. A multicenter trial, sponsored by the National Institutes of Health, is being conducted to determine the efficacy of short-course therapy for UTI in children. If efficacious, short-course therapy may enable clinicians to limit the duration of exposure to antimicrobials to that needed to eradicate the offending uropathogen.",
"   </p>",
"   <p>",
"    In the meantime, we recommend a longer course of therapy for febrile children (usually 10 days) and a short course of therapy (three to five days) for immune competent children presenting without fever. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42937?source=see_link&amp;anchor=H22#H22\">",
"     \"Acute cystitis in children older than two years and adolescents\", section on 'Duration of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Response to therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Clinical response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical condition of most patients improves within 24 to 48 hours of initiation of appropriate antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mean time to resolution of fever is 24 hours, but fever may persist beyond 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/4\">",
"     4",
"    </a>",
"    ]. In a review of 288 children younger than two years who were admitted to a tertiary-care children's hospital with febrile UTI, 89 percent were afebrile within 48 hours of antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/41\">",
"     41",
"    </a>",
"    ]. No differences were noted between those who remained febrile &gt;48 hours and those who were afebrile within 48 hours with respect to bacteremia (42 and 35 percent, respectively), hydronephrosis (3 and 8 percent, respectively) and significant vesicoureteral reflux (VUR) (19 and 14 percent, respectively).",
"   </p>",
"   <p>",
"    In children whose clinical condition (other than persistent fever) worsens or fails to improve as expected within 48 hours of initiation of antimicrobial therapy, broadening antimicrobial therapy may be indicated if the culture and sensitivity results are not yet available. Most of the empiric regimens suggested above do not provide adequate coverage for",
"    <em>",
"     Enterococcus",
"    </em>",
"    .",
"   </p>",
"   <p>",
"    In addition, in children who worsen or fail to improve within 48 hours, renal and bladder ultrasonography (RBUS) should be performed as soon as possible (to evaluate the presence of a renal abscess or surgically correctable anatomic abnormalities or obstruction) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/3,42,43\">",
"     3,42,43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Repeat urine culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several observational studies suggest there is little utility in repeating the urine culture in children with UTI who are treated with an antibiotic to which their uropathogen is susceptible [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/41,44,45\">",
"     41,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accordingly, it is not necessary to routinely obtain repeat urine cultures during antimicrobial therapy to document sterilization of the urine, provided that the child has had the expected clinical response and the uropathogen is susceptible to the antibiotic that is used for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/41,44-46\">",
"     41,44-46",
"    </a>",
"    ]. However, urine cultures should be performed after 48 hours of therapy if the patient fails to respond clinically or if the uropathogen is not susceptible (intermediate or resistant) to the antibiotic that is being used for treatment. It is important to routinely perform susceptibility testing on the isolated uropathogens to avoid unnecessary delay in administration of appropriate therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522686272\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether the administration of prophylactic antibiotics after initial febrile UTI prevents recurrent urinary tract infection or renal scarring is uncertain. Randomized trials evaluating this question have had inconsistent results [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/47-52\">",
"     47-52",
"    </a>",
"    ]. A meta-analysis of individual data in infants and young children (2 to 24 months) without VUR and with VUR of grades I to IV did not detect a benefit for prophylaxis in preventing recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/3\">",
"     3",
"    </a>",
"    ]. However, some of the included trials had methodologic problems potentially biasing results toward no effect (eg, insufficient power; lack of blinding; non-stringent diagnostic criteria; inclusion of uncircumcised boys, which limits generalizability to populations where most boys are circumcised; and misclassification of asymptomatic bacteriuria as recurrent UTIs) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/53\">",
"     53",
"    </a>",
"    ]. The largest and best designed trial demonstrated that antimicrobial prophylaxis was moderately effective in reducing symptomatic recurrence (11 versus 17 percent); the reduction in absolute risk was greatest for children with grade III-V VUR (6.8 percentage points compared with 5.4 percentage points for children with grade I to II VUR and 1.8 percentage points for children without VUR) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More conclusive evidence on the benefits of antimicrobial prophylaxis is expected from the ongoing randomized intervention for vesicoureteral reflux (RIVUR) study comparing TMP-SMX prophylaxis and placebo in 600 children (two months to six years) with grade I to IV VUR following UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/54\">",
"     54",
"    </a>",
"    ]. The revised AAP practice guideline does not recommend prophylactic antimicrobials following the first febrile UTI in children 2 to 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/3\">",
"     3",
"    </a>",
"    ]. Pending results of the RIVUR study, we agree with this recommendation. However, if a voiding cystourethrogram (VCUG) is performed and demonstrates grade III or higher VUR, we suggest antimicrobial prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/62/41961?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of vesicoureteral reflux\", section on 'Grades III to V'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The United Kingdom&rsquo;s National Institute for Health and Clinical Excellence (NICE) guideline for UTI in children indicates that antibiotic prophylaxis should not be routinely recommended in infants and children following their first UTI, but may be warranted after recurrent UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7606?source=see_link&amp;anchor=H8#H8\">",
"     \"Long-term management and prevention of urinary tract infections in children\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549886516\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal parenchymal inflammation during urinary tract infections (UTI) may lead to renal scarring, although the predisposing factors are not well understood [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/55\">",
"     55",
"    </a>",
"    ]. The role of renal parenchymal inflammation in the development of renal scars, and the potential role of anti-inflammatory agents in preventing renal scars has been evaluated in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. An observational study demonstrated that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    decreased urinary levels of interleukin-6 and interleukin-8 in children, suggesting a possible role for glucocorticoids in the prevention of scar formation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/57\">",
"     57",
"    </a>",
"    ]. This hypothesis was supported by a trial in which 84 children &lt;16 years with first episode of acute pyelonephritis and high risk of renal scar formation were randomly assigned to receive oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    or placebo in addition to antibiotic therapy (19 in the methylprednisolone group and 65 in the placebo group) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/58\">",
"     58",
"    </a>",
"    ]. Treatment with methylprednisolone was associated with decreased renal scarring at six months (33 versus 60 percent in the methylprednisolone and placebo groups, respectively) without significant adverse effects, relapse, or recurrence.",
"   </p>",
"   <p>",
"    Results of this small study are difficult to generalize because enrollment required 1) performance of a renal scintigram within 48 hours of diagnosis, which was not conducted in all patients, and 2) severe renal involvement in children who were all hospitalized. Additional studies are necessary to confirm these results and to determine the optimum glucocorticoid regimen before adjunctive glucocorticoids are routinely recommended in the treatment of UTI in children. A large randomized trial sponsored by the National Institutes of Health is being conducted to answer these questions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H880506880\">",
"    <span class=\"h2\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for imaging in young children with urinary tract infections (UTI) is to identify abnormalities of the genitourinary tract that require additional evaluation or management (eg, obstructive uropathies, dilating vesicoureteral reflux [VUR]). If such abnormalities are detected, steps can be taken to modify the risk of subsequent renal damage (eg, surgical intervention or antibiotic prophylaxis to prevent recurrent UTI).",
"   </p>",
"   <p>",
"    The ultimate value of detecting anatomic or functional abnormalities of the urinary tract depends upon the effectiveness of the interventions designed to prevent recurrent UTI and renal scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Evidence to support the utility of routine imaging in reducing long-term sequelae (renal scarring, hypertension, renal failure) is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/62-65\">",
"     62-65",
"    </a>",
"    ], and there is a lack of consensus about the optimal imaging strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/3,46,66-68\">",
"     3,46,66-68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prompt diagnosis and effective treatment of recurrent febrile UTI and treatment of bowel and bladder dysfunction that predisposes many children to UTI may be more important than identifying anatomic or functional genitourinary abnormalities after the first febrile UTI in preventing renal scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/3\">",
"     3",
"    </a>",
"    ]. The risk of renal scarring increases with recurrent episodes of pyelonephritis, from approximately 5 percent after the first episode to 10 percent after the second, 20 percent after the third, 40 percent after the fourth, and 60 percent after the fifth [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/69\">",
"     69",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal and bladder ultrasonography (RBUS) is a non-invasive test that can demonstrate the size and shape of the kidneys, the presence of duplication and dilatation of the ureters, and the existence of gross anatomic abnormalities. RBUS can also identify renal or perirenal abscess or pyonephrosis in children with acute UTI who fail to improve with antimicrobial therapy. It is not reliable in detecting renal scarring or VUR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=see_link\">",
"     \"Presentation, diagnosis, and clinical course of vesicoureteral reflux\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RBUS is estimated to yield management-altering abnormalities (ie, requiring additional evaluation, surgery) in only 1 to 2 percent of cases of first febrile UTI in young children 2 to 24 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/1,3,47,70,71\">",
"     1,3,47,70,71",
"    </a>",
"    ]. The false positive rate is between 2 and 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/3\">",
"     3",
"    </a>",
"    ]. The major advantage of RBUS is the lack of exposure to radiation.",
"   </p>",
"   <p>",
"    Given the potentially large benefit of detecting correctible malformations for a small number of children and the low risk of harm, we suggest RBUS for the following children: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children younger than two years of age with a first febrile UTI",
"     </li>",
"     <li>",
"      Children of any age with recurrent febrile UTIs",
"     </li>",
"     <li>",
"      Children of any age with a UTI who have a family history of renal or urologic disease, poor growth, or hypertension (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"       calculator 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Children who do not respond as expected to appropriate antimicrobial therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, many women have prenatal ultrasonography after 30 to 32 weeks of gestation &ndash; a time at which the urinary tract is fully developed; we may elect not to perform RBUS (in children of any age) if prenatal ultrasonography that was performed at a reputable center was normal and the study results are accessible [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics (AAP) recommends RBUS for all infants and children 2 to 24 months following their first febrile UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/3\">",
"     3",
"    </a>",
"    ]. The United Kingdom&rsquo;s National Institute for Health and Clinical Excellence (NICE) guideline on UTI in children recommends RBUS for infants younger than six months and for children older than six months who have atypical or recurrent UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/46\">",
"     46",
"    </a>",
"    ]. They define atypical UTI as serious illness, poor urine flow, abdominal or bladder mass; elevated creatinine, septicemia, infection with an organism other than",
"    <em>",
"     E. coli",
"    </em>",
"    , and failure to respond to antibiotics within 48 hours; they define recurrence as &ge;2 episodes of upper UTI, one episode of upper UTI plus &ge;1 episode of lower UTI, or &ge;3 episodes of lower UTI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H973874071\">",
"    <span class=\"h3\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the RBUS should be performed depends upon the clinical situation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/3\">",
"     3",
"    </a>",
"    ]. In infants and young children with unusually severe illness or failure to improve as expected after initiation of antimicrobial therapy, RBUS should be performed as soon as possible during the acute phase of illness to identify complications (eg, renal or perirenal abscess, pyonephrosis). However, for infants and young children who respond as expected to appropriate antimicrobial therapy, RBUS should be performed after the acute phase (to reduce the risk of false positive results secondary to renal inflammation during the acute episode) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/3,46\">",
"     3,46",
"    </a>",
"    ]. The decision to treat with prophylactic antibiotics pending results of imaging is discussed above. (See",
"    <a class=\"local\" href=\"#H522686272\">",
"     'Prophylactic antibiotics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Voiding cystourethrogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vesicoureteral reflux (VUR) is the retrograde passage of urine from the bladder into the upper urinary tract. Approximately 40 percent of young children with a first febrile UTI have VUR [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/4\">",
"     4",
"    </a>",
"    ]. The voiding cystourethrogram (VCUG) is the test of choice to establish the presence and degree of VUR. The procedure involves catheterization to fill the bladder with a radiopaque or radioactive liquid and recording of VUR during voiding. VCUG is expensive, invasive, and may miss a significant portion of children who are at risk for renal scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/61\">",
"     61",
"    </a>",
"    ]. The radiation exposure depends upon the technique and equipment used (the pediatric effective dose estimate ranges from 0.03 to 0.3 mSV) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=see_link&amp;anchor=H7#H7\">",
"     \"Presentation, diagnosis, and clinical course of vesicoureteral reflux\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The utility of the routine VCUG in the evaluation of children with UTI has been questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/1,3,46,63,64,67\">",
"     1,3,46,63,64,67",
"    </a>",
"    ]. The controversy centers on the changing view of the role of VUR in the development of renal damage and progressive kidney disease (VUR is neither necessary nor sufficient for the development of renal scars) and the uncertainty regarding the effectiveness of medical or surgical management of VUR in reducing the risk of renal scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H522686272\">",
"     'Prophylactic antibiotics'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=see_link&amp;anchor=H18#H18\">",
"     \"Presentation, diagnosis, and clinical course of vesicoureteral reflux\", section on 'Role in renal scarring and chronic kidney disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/62/41961?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of vesicoureteral reflux\", section on 'Choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of renal scarring is increased in children with VUR compared with children without VUR (41 versus 17 percent in a systematic review) and increases with increasing grades of VUR [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/61\">",
"     61",
"    </a>",
"    ]. However, it remains unclear whether the benefits of detection and treatment of VUR outweigh the risks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pending results of the ongoing randomized intervention for vesicoureteral reflux (RIVUR) study comparing",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) prophylaxis and placebo in 600 children (two months to six years) with grade I to IV VUR following UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/54\">",
"     54",
"    </a>",
"    ], we suggest VCUG to evaluate possible VUR for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children of any age with two or more febrile UTIs.",
"     </li>",
"     <li>",
"      Children of any age with a first febrile UTI who have a family history of renal or urologic disease; or poor growth; hypertension (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). Urinary tract anomalies are more frequent among children with UTI caused by pathogens other than",
"      <em>",
"       E. coli",
"      </em>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/70,75,76\">",
"       70,75,76",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=see_link&amp;anchor=H18#H18\">",
"       \"Presentation, diagnosis, and clinical course of vesicoureteral reflux\", section on 'Role in renal scarring and chronic kidney disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a VCUG is performed and demonstrates grade III or higher VUR, we suggest antimicrobial prophylaxis.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H522686272\">",
"     'Prophylactic antibiotics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In contrast to the 1999 guidelines, the 2011 AAP clinical practice guideline no longer recommends routine VCUG for infants and young children 2 to 24 months of age after the first febrile UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/3\">",
"     3",
"    </a>",
"    ]. The recommendation is to postpone the VCUG until the second febrile UTI unless there are atypical or complex clinical circumstances or the RBUS reveals hydronephrosis, scarring, or other findings suggestive of high-grade (IV or V) VUR or obstructive uropathy. According to the guideline, the benefit of avoiding radiation exposure and discomfort in the majority of patients outweighs delayed detection of a small number of cases of high-grade reflux or surgically correctible abnormalities. However, the guideline acknowledges that parent preferences may play a role in the decision to perform VCUG.",
"   </p>",
"   <p>",
"    The United Kingdom&rsquo;s NICE guideline suggests VCUG for infants &lt;6 months with atypical or recurrent UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/46\">",
"     46",
"    </a>",
"    ]. They define atypical UTI as serious illness, poor urine flow, abdominal or bladder mass; elevated creatinine, septicemia, infection with an organism other than",
"    <em>",
"     E. coli",
"    </em>",
"    , and failure to respond to antibiotics within 48 hours; they define recurrence as &ge;2 episodes of upper UTI, one episode of upper UTI plus &ge;1 episode of lower UTI, or &ge;3 episodes of lower UTI. The NICE guidelines also suggest that VCUG may be warranted for children six months to three years with atypical or recurrent UTI and dilation on ultrasonography, poor urine flow, non-",
"    <em>",
"     E. coli",
"    </em>",
"    infection, or family history of VUR. They define atypical UTI as serious illness, poor urine flow, abdominal or bladder mass; elevated creatinine, septicemia, infection with an organism other than",
"    <em>",
"     E. coli",
"    </em>",
"    , and failure to respond to antibiotics within 48 hours; they define recurrence as &ge;2 episodes of upper UTI, one episode of upper UTI plus &ge;1 episode of lower UTI, or &ge;3 episodes of lower UTI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H973874079\">",
"    <span class=\"h3\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although VCUG is often scheduled several weeks after UTI, it may be performed as soon as the patient is asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/77\">",
"     77",
"    </a>",
"    ]. Early imaging (as early as the first week) does not appear to falsely increase the detection of VUR [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/78-81\">",
"     78-81",
"    </a>",
"    ]. To avoid the use of prophylactic antibiotics in children without VUR, we prefer to conduct VCUGs during the last days of antimicrobial therapy or immediately after completion of antimicrobial therapy for UTI. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Renal scintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal scintigraphy using",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/22/8548?source=see_link\">",
"     dimercaptosuccinic acid",
"    </a>",
"    (DMSA) can be used to detect acute pyelonephritis and renal scarring in the acute and chronic settings, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/1,3,82\">",
"     1,3,82",
"    </a>",
"    ]. DMSA is injected intravenously, and uptake by the kidney is measured two to four hours later. Areas of decreased uptake represent pyelonephritis or scarring. DMSA scans are expensive, invasive, and expose children to radiation (the pediatric effective dose estimate ranges from 0.3 to 3 mSV) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of renal scintigraphy in the management of children with acute UTI is controversial. Scintigraphy at the time of an acute UTI provides information about the extent of renal parenchymal involvement. In addition, DMSA will identify most (&gt;70 percent) children with moderate to severe VUR (grade III or higher) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. This observation has prompted some experts to suggest that DMSA be used as the initial imaging test to identify children at higher risk for renal scarring (the &ldquo;top down&rdquo; approach) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, using DMSA as the initial test to identify high-risk children is more expensive, and involves greater exposure to radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/87\">",
"     87",
"    </a>",
"    ]. Furthermore, since most young febrile children with UTI have pyelonephritis and a positive DMSA, this strategy may lead to identification of a large number of children who may or may not be at risk for future UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/1,61\">",
"     1,61",
"    </a>",
"    ]. In a systematic review of 33 studies, approximately 60 percent of children with initial UTI had DMSA scans consistent with acute pyelonephritis in the acute phase of illness, but only 15 percent had renal scarring at follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/61\">",
"     61",
"    </a>",
"    ]. It is unclear how to best manage children with positive acute-phase DMSA scan. Careful clinical follow-up of all children with UTI may obviate the need for routine DMSA. (See",
"    <a class=\"local\" href=\"#H522687481\">",
"     'Follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We suggest not using DMSA in the routine evaluation of children with first UTI. This is consistent with the AAP and NICE guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/3,46\">",
"     3,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some experts recommend DMSA 6 to 12 months after acute infection to detect the formation of scarring which would require follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. The NICE guidelines recommend DMSA four to six months after acute infection for children younger than three years with atypical or recurrent UTI and for children older than three years with recurrent UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/46\">",
"     46",
"    </a>",
"    ]. They define atypical UTI as serious illness, poor urine flow, abdominal or bladder mass; elevated creatinine, septicemia, infection with an organism other than",
"    <em>",
"     E. coli",
"    </em>",
"    , and failure to respond to antibiotics within 48 hours; they define recurrence as &ge;2 episodes of upper UTI, one episode of upper UTI plus &ge;1 episode of lower UTI, or &ge;3 episodes of lower UTI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522687481\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent urinary tract infection (UTI) is a risk factor for renal scarring. Parents of infants and young children who have been treated for a febrile UTI and children with bowel and bladder dysfunction (a risk factor for recurrent UTI) should be instructed to seek prompt evaluation for subsequent febrile illnesses to ensure prompt recognition and treatment of recurrent UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/3,46,53\">",
"     3,46,53",
"    </a>",
"    ]. The evaluation of these episodes should include urinalysis and urine culture [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/1\">",
"     1",
"    </a>",
"    ]. Among children younger than six years, the risk of recurrence appears to be increased in those who are white (hazard ratio [HR], 2.0), age three to five years (HR ~2.5), and those with grade IV to V VUR (HR 4.38) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary care follow-up for infants and young children who have had a febrile UTI should include regular monitoring of height, weight, and blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H880507219\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential indications for referral to a nephrologist or urologist with expertise in children include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dilating vesicoureteral reflux (Grades III to V) or obstructive uropathy",
"     </li>",
"     <li>",
"      Renal abnormalities",
"     </li>",
"     <li>",
"      Impaired kidney function",
"     </li>",
"     <li>",
"      Elevated blood pressure",
"     </li>",
"     <li>",
"      Bowel and bladder dysfunction refractory to primary care measures (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7606?source=see_link&amp;anchor=H5#H5\">",
"       \"Long-term management and prevention of urinary tract infections in children\", section on 'Children with bowel and bladder dysfunction'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The short-term outcome of first urinary tract infection (UTI) in children (&lt;19 years) was described in a systematic review of 33 studies, including 4891 children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-five percent had vesicoureteral reflux (VUR); 2.5 percent had grade IV or V VUR",
"     </li>",
"     <li>",
"      VUR was associated with an increased risk of developing acute pyelonephritis (relative risk [RR] 1.5, 95% CI 1.1-1.9) and renal scarring (RR 2.6, 95% CI 1.7-3.9); grade III VUR was associated with increased risk of renal scarring compared with lower grades (RR 2.1, 95% CI 1.4-3.2)",
"     </li>",
"     <li>",
"      Fifteen percent (95% CI 11-18 percent) of children had evidence of renal scarring on follow-up",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/22/8548?source=see_link\">",
"       dimercaptosuccinic acid",
"      </a>",
"      (DMSA) scan (5 to 24 months later); the long-term significance of scarring, as identified by DMSA, remains to be determined",
"     </li>",
"     <li>",
"      Eight percent (95% CI 5-11 percent) of children had at least one recurrence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factors for recurrence among children younger than six years include white race (hazard ratio [HR], 2.0), age three to five years (HR ~2.5), and grade IV to V VUR (HR 4.38) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Predicting which children with UTI will develop long-term sequelae remains difficult. A systematic review of the literature found only four prospective, relatively small studies addressing this question [",
"    <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/90\">",
"     90",
"    </a>",
"    ]. The large majority of children with UTI have no long-term sequelae, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 111 high-risk girls who were followed for 6 to 32 years after their initial UTI, only seven (6 percent) had decreased glomerular filtration rate (GFR), and none developed chronic kidney disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study of 68 children with history of urographic renal scarring who were followed for 16 to 26 years after their index UTI, median GFR [",
"      <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/62\">",
"       62",
"      </a>",
"      ] and mean 24-hour ambulatory blood pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/92\">",
"       92",
"      </a>",
"      ] were no different in children with and without urographic renal scarring. No child developed chronic kidney disease.",
"     </li>",
"     <li>",
"      In a study of 226 children with UTI followed for one to 41 years, two developed chronic kidney disease that appeared to be attributable to the UTIs [",
"      <a class=\"abstract\" href=\"UTD.htm?27/1/27674/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognosis for children with nonfebrile UTI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42937?source=see_link&amp;anchor=H25#H25\">",
"     \"Acute cystitis in children older than two years and adolescents\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/58/38818?source=see_link\">",
"       \"Patient information: Urinary tract infections in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/58/38818?source=see_link\">",
"       \"Patient information: Urinary tract infections in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most children with urinary tract infection (UTI) can be managed as outpatients. Indications for hospitalization may include age &lt;2 months, immunocompromised patient, vomiting or inability to tolerate oral medication, lack of outpatient follow-up, and failure to respond to outpatient therapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Decision to hospitalize'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Empiric antimicrobial therapy immediately after appropriate urine collection is warranted in children with suspected UTI and a positive urinalysis. This is particularly true for young children with fever (especially if &gt;39&deg;C [102.2&deg;F] or &gt;48 hours), ill appearance, costovertebral angle tenderness, known immune deficiency, or known urologic abnormality. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Empiric therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that empiric therapy for UTI in children include an antibiotic that provides adequate coverage for",
"      <em>",
"       Escherichia coli",
"      </em>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The agent of choice should be guided by local resistance patterns. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Choice of agent'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest a third-generation cephalosporin (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/32/38404?source=see_link\">",
"       cefixime",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/2/6181?source=see_link\">",
"       cefdinir",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/44/24260?source=see_link\">",
"       ceftibuten",
"      </a>",
"      ) as the first-line oral agent in the treatment of UTI in children without genitourinary abnormalities (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ).",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"       Amoxicillin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       ampicillin",
"      </a>",
"      should be added if enterococcal infection is suspected. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Oral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Third- or fourth-generation cephalosporins (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"       cefepime",
"      </a>",
"      ) and aminoglycosides (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      ) are appropriate first-line parenteral agents for empiric treatment of UTI in children. Definitive therapy is based upon the results of urine culture and sensitivities. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Parenteral therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The duration of therapy depends upon the age of the child and the clinical scenario. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Febrile children are usually treated for 10 days",
"     </li>",
"     <li>",
"      Afebrile children are usually treated for shorter periods (3 to 5 days) (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Duration of therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42937?source=see_link\">",
"       \"Acute cystitis in children older than two years and adolescents\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical condition of most patients improves within 24 to 48 hours of initiation of appropriate antimicrobial therapy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children whose clinical condition worsens or fails to improve as expected within 24 to 48 hours of initiation of antimicrobial therapy, broadening of empiric therapy may be indicated. Renal bladder ultrasonography (RBUS) should be performed as soon as possible to evaluate the presence of renal abscess or surgically correctable anatomic abnormalities or obstruction. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest routine RBUS after first febrile UTI in children younger than two years who did not have normal prenatal ultrasonography at a reputable center at &gt;30 to 32 weeks of gestation. We also suggest RBUS for children of any age with recurrent febrile UTIs and children of any age with a first UTI who have poor growth, hypertension, or a family history of renal or urologic disease. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Ultrasonography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to earlier suggestions for evaluation after an initial episode, we now suggest voiding cystourethrogram (VCUG) to evaluate possible vesicoureteral reflux (VUR) for children of any age with &ge;2 febrile UTIs or a first febrile UTI and any of the following: a family history of renal or urologic disease; poor growth; or hypertension. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Voiding cystourethrogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of children with UTI have no long-term sequelae. Prediction of long-term sequelae in children with UTI remains difficult. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/1\">",
"      Hoberman A, Charron M, Hickey RW, et al. Imaging studies after a first febrile urinary tract infection in young children. N Engl J Med 2003; 348:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/2\">",
"      Larcombe J. Urinary tract infection in children. Clin Evid 2005; :429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/3\">",
"      Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics 2011; 128:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/4\">",
"      Hoberman A, Wald ER, Hickey RW, et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics 1999; 104:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/5\">",
"      Hodson EM, Willis NS, Craig JC. Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev 2007; :CD003772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/6\">",
"      Chang SL, Shortliffe LD. Pediatric urinary tract infections. Pediatr Clin North Am 2006; 53:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/7\">",
"      Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary tract infections. Clin Microbiol Rev 2005; 18:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/8\">",
"      Roberts JA, Kaack MB, Baskin G. Treatment of experimental pyelonephritis in the monkey. J Urol 1990; 143:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/9\">",
"      Smellie JM, Poulton A, Prescod NP. Retrospective study of children with renal scarring associated with reflux and urinary infection. BMJ 1994; 308:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/10\">",
"      Smellie JM, Ransley PG, Normand IC, et al. Development of new renal scars: a collaborative study. Br Med J (Clin Res Ed) 1985; 290:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/11\">",
"      Hiraoka M, Hashimoto G, Tsuchida S, et al. Early treatment of urinary infection prevents renal damage on cortical scintigraphy. Pediatr Nephrol 2003; 18:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/12\">",
"      Doganis D, Siafas K, Mavrikou M, et al. Does early treatment of urinary tract infection prevent renal damage? Pediatrics 2007; 120:e922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/13\">",
"      Fern&aacute;ndez-Men&eacute;ndez JM, M&aacute;laga S, Matesanz JL, et al. Risk factors in the development of early technetium-99m dimercaptosuccinic acid renal scintigraphy lesions during first urinary tract infection in children. Acta Paediatr 2003; 92:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/14\">",
"      Oh MM, Kim JW, Park MG, et al. The impact of therapeutic delay time on acute scintigraphic lesion and ultimate scar formation in children with first febrile UTI. Eur J Pediatr 2012; 171:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/15\">",
"      Shaikh N, Morone NE, Lopez J, et al. Does this child have a urinary tract infection? JAMA 2007; 298:2895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/16\">",
"      Ladhani S, Gransden W. Increasing antibiotic resistance among urinary tract isolates. Arch Dis Child 2003; 88:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/17\">",
"      Allen UD, MacDonald N, Fuite L, et al. Risk factors for resistance to \"first-line\" antimicrobials among urinary tract isolates of Escherichia coli in children. CMAJ 1999; 160:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/18\">",
"      Ismaili K, Wissing KM, Lolin K, et al. Characteristics of first urinary tract infection with fever in children: a prospective clinical and imaging study. Pediatr Infect Dis J 2011; 30:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/19\">",
"      Goldraich NP, Manfroi A. Febrile urinary tract infection: Escherichia coli susceptibility to oral antimicrobials. Pediatr Nephrol 2002; 17:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/20\">",
"      McLoughlin TG Jr, Joseph MM. Antibiotic resistance patterns of uropathogens in pediatric emergency department patients. Acad Emerg Med 2003; 10:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/21\">",
"      Prais D, Straussberg R, Avitzur Y, et al. Bacterial susceptibility to oral antibiotics in community acquired urinary tract infection. Arch Dis Child 2003; 88:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/22\">",
"      Lutter SA, Currie ML, Mitz LB, Greenbaum LA. Antibiotic resistance patterns in children hospitalized for urinary tract infections. Arch Pediatr Adolesc Med 2005; 159:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/23\">",
"      Cheng CH, Tsai MH, Huang YC, et al. Antibiotic resistance patterns of community-acquired urinary tract infections in children with vesicoureteral reflux receiving prophylactic antibiotic therapy. Pediatrics 2008; 122:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/24\">",
"      Hom J. Are oral antibiotics equivalent to intravenous antibiotics for the initial management of pyelonephritis in children? Paediatr Child Health 2010; 15:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/25\">",
"      Neuhaus TJ, Berger C, Buechner K, et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. Eur J Pediatr 2008; 167:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/26\">",
"      Bonsu BK, Shuler L, Sawicki L, et al. Susceptibility of recent bacterial isolates to cefdinir and selected antibiotics among children with urinary tract infections. Acad Emerg Med 2006; 13:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/27\">",
"      Montini G, Toffolo A, Zucchetta P, et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial. BMJ 2007; 335:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/28\">",
"      Bradley JS, Jackson MA, Committee on Infectious Diseases, American Academy of Pediatrics. The use of systemic and topical fluoroquinolones. Pediatrics 2011; 128:e1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/29\">",
"      Pickering LK. Antimicrobial resistance among enteric pathogens. Semin Pediatr Infect Dis 2004; 15:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/30\">",
"      McNeeley DF, Eckert SJ, Noel GJ. Antimicrobial-resistant enterococcal isolates from fluoroquinolone-naive children. Pediatr Infect Dis J 2000; 19:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/31\">",
"      Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003; 37:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/32\">",
"      Arrieta AC, Bradley JS. Empiric use of cefepime in the treatment of serious urinary tract infections in children. Pediatr Infect Dis J 2001; 20:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/33\">",
"      Jones ME, Karlowsky JA, Draghi DC, et al. Rates of antimicrobial resistance among common bacterial pathogens causing respiratory, blood, urine, and skin and soft tissue infections in pediatric patients. Eur J Clin Microbiol Infect Dis 2004; 23:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/34\">",
"      Shaw KN, Gorelick MH. Urinary tract infection in the pediatric patient. Pediatr Clin North Am 1999; 46:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/35\">",
"      Gauthier M, Chevalier I, Sterescu A, et al. Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center. Pediatrics 2004; 114:e469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/36\">",
"      Lieu TA, Baskin MN, Schwartz JS, Fleisher GR. Clinical and cost-effectiveness of outpatient strategies for management of febrile infants. Pediatrics 1992; 89:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/37\">",
"      Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics 2004; 114:e111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/38\">",
"      Conway PH, Cnaan A, Zaoutis T, et al. Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. JAMA 2007; 298:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/39\">",
"      Paschke AA, Zaoutis T, Conway PH, et al. Previous antimicrobial exposure is associated with drug-resistant urinary tract infections in children. Pediatrics 2010; 125:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/40\">",
"      Michael M, Hodson EM, Craig JC, et al. Short versus standard duration oral antibiotic therapy for acute urinary tract infection in children. Cochrane Database Syst Rev 2003; :CD003966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/41\">",
"      Bachur R. Nonresponders: prolonged fever among infants with urinary tract infections. Pediatrics 2000; 105:E59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/42\">",
"      Dacher JN, Hitzel A, Avni FE, Vera P. Imaging strategies in pediatric urinary tract infection. Eur Radiol 2005; 15:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/43\">",
"      Cheng CH, Tsai MH, Su LH, et al. Renal abscess in children: a 10-year clinical and radiologic experience in a tertiary medical center. Pediatr Infect Dis J 2008; 27:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/44\">",
"      Oreskovic NM, Sembrano EU. Repeat urine cultures in children who are admitted with urinary tract infections. Pediatrics 2007; 119:e325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/45\">",
"      Currie ML, Mitz L, Raasch CS, Greenbaum LA. Follow-up urine cultures and fever in children with urinary tract infection. Arch Pediatr Adolesc Med 2003; 157:1237.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Urinary tract infection in children. August 2007. file://www.nice.org.uk/CG54 (Accessed on September 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/47\">",
"      Montini G, Rigon L, Zucchetta P, et al. Prophylaxis after first febrile urinary tract infection in children? A multicenter, randomized, controlled, noninferiority trial. Pediatrics 2008; 122:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/48\">",
"      Craig JC, Simpson JM, Williams GJ, et al. Antibiotic prophylaxis and recurrent urinary tract infection in children. N Engl J Med 2009; 361:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/49\">",
"      Garin EH, Olavarria F, Garcia Nieto V, et al. Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study. Pediatrics 2006; 117:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/50\">",
"      Pennesi M, Travan L, Peratoner L, et al. Is antibiotic prophylaxis in children with vesicoureteral reflux effective in preventing pyelonephritis and renal scars? A randomized, controlled trial. Pediatrics 2008; 121:e1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/51\">",
"      Roussey-Kesler G, Gadjos V, Idres N, et al. Antibiotic prophylaxis for the prevention of recurrent urinary tract infection in children with low grade vesicoureteral reflux: results from a prospective randomized study. J Urol 2008; 179:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/52\">",
"      Brandstr&ouml;m P, Esbj&ouml;rner E, Herthelius M, et al. The Swedish reflux trial in children: III. Urinary tract infection pattern. J Urol 2010; 184:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/53\">",
"      Hoberman A, Keren R. Antimicrobial prophylaxis for urinary tract infection in children. N Engl J Med 2009; 361:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/54\">",
"      Keren R, Carpenter MA, Hoberman A, et al. Rationale and design issues of the Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR) study. Pediatrics 2008; 122 Suppl 5:S240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/55\">",
"      Montini G, Tullus K, Hewitt I. Febrile urinary tract infections in children. N Engl J Med 2011; 365:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/56\">",
"      Pohl HG, Rushton HG, Park JS, et al. Adjunctive oral corticosteroids reduce renal scarring: the piglet model of reflux and acute experimental pyelonephritis. J Urol 1999; 162:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/57\">",
"      Sharifian M, Anvaripour N, Karimi A, et al. The role of dexamethasone on decreasing urinary cytokines in children with acute pyelonephritis. Pediatr Nephrol 2008; 23:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/58\">",
"      Huang YY, Chen MJ, Chiu NT, et al. Adjunctive oral methylprednisolone in pediatric acute pyelonephritis alleviates renal scarring. Pediatrics 2011; 128:e496.",
"     </a>",
"    </li>",
"    <li>",
"     Corticosteroids for children with febrile urinary tract infections. file://clinicaltrials.gov/ct2/show/NCT01391793 (Accessed on October 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/60\">",
"      Keren R. Imaging and treatment strategies for children after first urinary tract infection. Curr Opin Pediatr 2007; 19:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/61\">",
"      Shaikh N, Ewing AL, Bhatnagar S, Hoberman A. Risk of renal scarring in children with a first urinary tract infection: a systematic review. Pediatrics 2010; 126:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/62\">",
"      Wennerstr&ouml;m M, Hansson S, Jodal U, et al. Renal function 16 to 26 years after the first urinary tract infection in childhood. Arch Pediatr Adolesc Med 2000; 154:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/63\">",
"      Verrier Jones K. Time to review the value of imaging after urinary tract infection in infants. Arch Dis Child 2005; 90:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/64\">",
"      Moorthy I, Easty M, McHugh K, et al. The presence of vesicoureteric reflux does not identify a population at risk for renal scarring following a first urinary tract infection. Arch Dis Child 2005; 90:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/65\">",
"      Westwood ME, Whiting PF, Cooper J, et al. Further investigation of confirmed urinary tract infection (UTI) in children under five years: a systematic review. BMC Pediatr 2005; 5:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/66\">",
"      Wan J, Skoog SJ, Hulbert WC, et al. Section on Urology response to new Guidelines for the diagnosis and management of UTI. Pediatrics 2012; 129:e1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/67\">",
"      Roberts KB, Finnell SM, Downs SM. Response to the AAP Section on Urology concerns about the AAP Urinary Tract Infection Guideline. Pediatrics 2012; 129:e1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/68\">",
"      La Scola C, De Mutiis C, Hewitt IK, et al. Different Guidelines for Imaging After First UTI in Febrile Infants: Yield, Cost, and Radiation. Pediatrics 2013; 131:e665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/69\">",
"      Jodal U. The natural history of bacteriuria in childhood. Infect Dis Clin North Am 1987; 1:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/70\">",
"      Friedman S, Reif S, Assia A, et al. Clinical and laboratory characteristics of non-E. coli urinary tract infections. Arch Dis Child 2006; 91:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/71\">",
"      Alon US, Ganapathy S. Should renal ultrasonography be done routinely in children with first urinary tract infection? Clin Pediatr (Phila) 1999; 38:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/72\">",
"      Chitty LS, Hunt GH, Moore J, Lobb MO. Effectiveness of routine ultrasonography in detecting fetal structural abnormalities in a low risk population. BMJ 1991; 303:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/73\">",
"      Miron D, Daas A, Sakran W, et al. Is omitting post urinary-tract-infection renal ultrasound safe after normal antenatal ultrasound? An observational study. Arch Dis Child 2007; 92:502.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Radiology. ACR Appropriateness Criteria. Urinary Tract Infection--Child. file://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria/pdf/ExpertPanelonPediatricImaging/urinarytractinfectionChildDoc10.aspx (Accessed on September 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/75\">",
"      Honkinen O, Lehtonen OP, Ruuskanen O, et al. Cohort study of bacterial species causing urinary tract infection and urinary tract abnormalities in children. BMJ 1999; 318:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/76\">",
"      Honkinen O, Jahnukainen T, Mertsola J, et al. Bacteremic urinary tract infection in children. Pediatr Infect Dis J 2000; 19:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/77\">",
"      Hoberman A, Wald ER. Treatment of urinary tract infections. Pediatr Infect Dis J 1999; 18:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/78\">",
"      McDonald A, Scranton M, Gillespie R, et al. Voiding cystourethrograms and urinary tract infections: how long to wait? Pediatrics 2000; 105:E50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/79\">",
"      Mahant S, To T, Friedman J. Timing of voiding cystourethrogram in the investigation of urinary tract infections in children. J Pediatr 2001; 139:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/80\">",
"      Sathapornwajana P, Dissaneewate P, McNeil E, Vachvanichsanong P. Timing of voiding cystourethrogram after urinary tract infection. Arch Dis Child 2008; 93:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/81\">",
"      Doganis D, Mavrikou M, Delis D, et al. Timing of voiding cystourethrography in infants with first time urinary infection. Pediatr Nephrol 2009; 24:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/82\">",
"      Craig JC, Wheeler DM, Irwig L, Howman-Giles RB. How accurate is dimercaptosuccinic acid scintigraphy for the diagnosis of acute pyelonephritis? A meta-analysis of experimental studies. J Nucl Med 2000; 41:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/83\">",
"      Hansson S, Dhamey M, Sigstr&ouml;m O, et al. Dimercapto-succinic acid scintigraphy instead of voiding cystourethrography for infants with urinary tract infection. J Urol 2004; 172:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/84\">",
"      Preda I, Jodal U, Sixt R, et al. Normal dimercaptosuccinic acid scintigraphy makes voiding cystourethrography unnecessary after urinary tract infection. J Pediatr 2007; 151:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/85\">",
"      Tseng MH, Lin WJ, Lo WT, et al. Does a normal DMSA obviate the performance of voiding cystourethrography in evaluation of young children after their first urinary tract infection? J Pediatr 2007; 150:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/86\">",
"      Pohl HG, Belman AB. The \"top-down\" approach to the evaluation of children with febrile urinary tract infection. Adv Urol 2009; :783409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/87\">",
"      Routh JC, Grant FD, Kokorowski PJ, et al. Economic and radiation costs of initial imaging approaches after a child's first febrile urinary tract infection. Clin Pediatr (Phila) 2012; 51:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/88\">",
"      Montini G, Zucchetta P, Tomasi L, et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics 2009; 123:e239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/89\">",
"      Marks SD, Gordon I, Tullus K. Imaging in childhood urinary tract infections: time to reduce investigations. Pediatr Nephrol 2008; 23:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/90\">",
"      Salo J, Ik&auml;heimo R, Tapiainen T, Uhari M. Childhood urinary tract infections as a cause of chronic kidney disease. Pediatrics 2011; 128:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/91\">",
"      Martinell J, Lidin-Janson G, Jagenburg R, et al. Girls prone to urinary infections followed into adulthood. Indices of renal disease. Pediatr Nephrol 1996; 10:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/92\">",
"      Wennerstr&ouml;m M, Hansson S, Hedner T, et al. Ambulatory blood pressure 16-26 years after the first urinary tract infection in childhood. J Hypertens 2000; 18:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/1/27674/abstract/93\">",
"      Smellie JM, Prescod NP, Shaw PJ, et al. Childhood reflux and urinary infection: a follow-up of 10-41 years in 226 adults. Pediatr Nephrol 1998; 12:727.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5991 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-ECB61E16A9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_1_27674=[""].join("\n");
var outline_f27_1_27674=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Decision to hospitalize",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ANTIBIOTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Oral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Parenteral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H65841353\">",
"      Outpatient parenteral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Recent antibiotic exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H624406996\">",
"      - Recurrent UTI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Clinical response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Repeat urine culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H522686272\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H549886516\">",
"      ADJUNCTIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H880506880\">",
"      Rationale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H973874071\">",
"      - Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Voiding cystourethrogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H973874079\">",
"      - Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Renal scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H522687481\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H880507219\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42937?source=related_link\">",
"      Acute cystitis in children older than two years and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=related_link\">",
"      Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=related_link\">",
"      Clinical presentation and evaluation of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26360?source=related_link\">",
"      Epidemiology and risk factors for urinary tract infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7606?source=related_link\">",
"      Long-term management and prevention of urinary tract infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/62/41961?source=related_link\">",
"      Management of vesicoureteral reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/58/38818?source=related_link\">",
"      Patient information: Urinary tract infections in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=related_link\">",
"      Presentation, diagnosis, and clinical course of vesicoureteral reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14264?source=related_link\">",
"      Urinary tract infections in newborns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_1_27675="Complications of abdominal paracentesis";
var content_f27_1_27675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complications of abdominal paracentesis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Leak of ascitic fluid",
"       </td>",
"       <td>",
"        5 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe hemorrhage",
"       </td>",
"       <td>",
"        0 to 0.97 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection due to paracentesis",
"       </td>",
"       <td>",
"        0.58 to 0.63 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Death associated with paracentesis",
"       </td>",
"       <td>",
"        0 to 0.39 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        de Gottardi A, Thevenot T, Spahr L, et al. Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Hep Gastro 2009; 7:906.",
"       </li>",
"       <li>",
"        Grabau CM, Crago SF, Hoff LK, et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004; 40:484.",
"       </li>",
"       <li>",
"        McVay PA, Toy PTCY. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991; 31:164.",
"       </li>",
"       <li>",
"        Pache I, Bilodeau M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment Pharmacol Ther 2005; 21:525.",
"       </li>",
"       <li>",
"        Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology 1988; 95:1351.",
"       </li>",
"       <li>",
"        Runyon BA. Paracentesis of ascitic fluid: a safe procedure. Arch Intern Med 1986; 146:2259.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_1_27675=[""].join("\n");
var outline_f27_1_27675=null;
var title_f27_1_27676="Renal cell CA UISS categories";
var content_f27_1_27676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prognosis of renal cell carcinoma according to University of California Los Angeles Integrated Staging System (UISS) categorization",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        UISS stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        1997 TNM stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Furman's grade",
"       </td>",
"       <td class=\"subtitle1\">",
"        ECOG PS",
"       </td>",
"       <td class=\"subtitle1\">",
"        Two-year survival (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Five-year survival (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        1, 2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        94",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        II",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        1, 2",
"       </td>",
"       <td>",
"        1 or more",
"       </td>",
"       <td rowspan=\"5\">",
"        89",
"       </td>",
"       <td rowspan=\"5\">",
"        67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        3, 4",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1 or more",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        III",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        2 to 4",
"       </td>",
"       <td>",
"        1 or more",
"       </td>",
"       <td rowspan=\"2\">",
"        66",
"       </td>",
"       <td rowspan=\"2\">",
"        39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        1, 2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        IV",
"       </td>",
"       <td rowspan=\"2\">",
"        IV",
"       </td>",
"       <td>",
"        3, 4",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td rowspan=\"2\">",
"        42",
"       </td>",
"       <td rowspan=\"2\">",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 3",
"       </td>",
"       <td>",
"        1 or more",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        V",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1 or more",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ECOG PS: Eastern Cooperative Oncology Group performance status.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Zisman A, Pantuck A, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19:1649. Copyright &copy;2001 American Society of Clinical Oncology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_1_27676=[""].join("\n");
var outline_f27_1_27676=null;
var title_f27_1_27677="Lead time bias B";
var content_f27_1_27677=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Lead-time bias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 233px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lead-time bias occurs when screening identifies disease at an earlier time but the time of death remains unchanged. In the above diagram, lead-time bias for population B creates the impression that patients diagnosed by screening have a longer survival, although actual mortality is unchanged. Population C does have improved survival, compared to the unscreened population A.",
"    <div class=\"footnotes\">",
"     O: onset of disease; Dx: diagnosis.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Fletcher RF, Fletcher SW. Prevention. In: Clinical Epidemiology: The Essentials, 4th ed. Lippincott Williams &amp; Wilkins, Baltimore, 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_1_27677=[""].join("\n");
var outline_f27_1_27677=null;
var title_f27_1_27678="Posterior needle bx bone tumor";
var content_f27_1_27678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior bone biopsy approach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The CT-guided needle biopsy of this osteosarcoma was performed using a posterior approach. Although targeting the lytic soft tissue component for sampling was appropriate, the posterior needle track would have been difficult to excise with the specimen, and could theoretically have compromised the surgery. In this case, however, amputation was performed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel Rosenthal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_1_27678=[""].join("\n");
var outline_f27_1_27678=null;
var title_f27_1_27679="Starlings forces muscles";
var content_f27_1_27679=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F72206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F72206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Starling's forces in muscle and glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 192px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Approximate values for Starling's forces in human muscle capillary and primate glomerulus. The capillary onoctic pressure rises in the glomerulus because of the filtration of relatively protein-free fluid. Units are mmHg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Guyton, AC, Textbook of Medical Physiology, 8th ed, Saunders, Philadelphia, 1991, chap.16, and Maddox, DA, Deen, WM, Brenner, BM, Kidney Int 1974; 5:271.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_1_27679=[""].join("\n");
var outline_f27_1_27679=null;
         